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CIP4 AND SRC IN PROMOTING THE MIGRATION AND INVASION OF BREAST CANCER  Publication No.________   Christina Stewart Pichot Supervisory Professor: Seth J. Corey, M.D.   Cellular  invasion  represents  a  critical  early  step  in  the  metastatic  cascade,  and many proteins have been identified as part of an “invasive signature.” The non‐receptor tyrosine kinase Src is commonly upregulated in breast cancers, often in conjunction with overexpression  of  EGFR.  Signaling  from  this  pathway  stimulates  cell  proliferation, migration, and  invasion and  frequently  involves proteins  that regulate  the cytoskeleton. My data demonstrates that inhibition of Src, using the small‐molecule inhibitor dasatinib, impairs cellular migration and invasion. Furthermore, Src inhibition sensitizes the cells to the  effects  of  the  chemotherapeutic  doxorubicin  resulting  in  dramatic,  synergistic inhibition  of  proliferation  with  combination  treatments.  The  Src‐targeted  protein  CIP4 (Cdc42‐interacting  protein  4)  associates  with  curved  plasma  membranes  to  scaffold complexes of Cdc42 and N‐WASp. In these experiments, I show that CIP4 overexpression correlates  with  triple‐negative  biomarker  status,  cellular  migration,  and  invasion  of (breast  cancer  cells.  Inhibition of CIP4 expression  significantly decreases migration and invasion. Furthermore, I demonstrate the novel finding that CIP4 localizes to invadopodia, which are finger‐like projections of the actin cytoskeleton that are associated with matrix degradation  and  cellular  invasion.  Depletion  of  CIP4  in  invasive  cells  impairs  the formation  of  invadopodia  and  the  degradation  of  gelatin.  Therefore,  CIP4  is  a  critical component of the invasive phenotype acquired by human breast cancer cells. In this body of work, I propose a model in which CIP4 promotes actin polymerization by stabilizing the active  conformation  of    N‐WASp.  CIP4  and  N‐WASp  are  both  phosphorylated  by  Src, implicating  this pathway  in Src‐dependent  cytoskeletal  rearragement. This  represents a novel role for F‐BAR proteins in migration and invasion. 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1.1.1   Etiology Breast  cancer  is  the  most  commonly  diagnosed  cancer  in  American  women, affecting  nearly  200,000  new  patients  every  year.  Currently,  there  are  more  than  2.5 million  women  living  in  the  US  with  a  history  of  breast  cancer  diagnosis.  Five‐year survival rates for patients diagnosed with localized or regional disease are encouraging: 98.3%  and  83.5%,  respectively.  However,  for  the  women  presenting  with  metastatic disease, the five‐year survival drops to a dismal 23.3% (2). Thus, targeting of metastatic disease represents an important area of research with strong clinical implications.    Although  having  a  mother  or  sister  with  breast  cancer  significantly  increases  a woman’s risk of developing breast cancer (3), less than 5% of breast cancer cases can be attributed  to  family history of  the disease (4, 5). This  leaves  the vast majority of breast cancers  as occurring due  to  environmental  effects  or unknown genetic  factors. Age  is  a primary  risk  factor;  65%  of  patients  are  over  the  age  of  55  at  diagnosis  (2).  Hormone therapy,  ionizing  radiation,  breast  density,  obesity,  and  excessive  alcohol  intake  all increase  the  lifetime  risk  of  developing  breast  cancer,  whereas  pregnancy  (especially early),  breast‐feeding,  and  exercise  are  associated  with  decreased  risk  (6,  7).  Many  of these risk factors hinge on the role of hormones, especially heightened levels of estrogen, in the development of breast cancer (8).    In general, cancer is defined as the uncontrolled growth of cells, which may or may not  spread  to  other  parts  of  the  body.  The  seminal  paper  by  Hanahan  and  Weinberg describes  the  “Hallmarks of Cancer”: uncontrolled growth, evasion of death (apoptosis), self‐sufficiency  in  growth  signals,  insensitivity  to  anti‐growth  signals,  angiogenesis,  and tissue  invasion/metastasis  (9).  Through  a  variety  of  mechanisms,  cancer  cells  acquire these basic capabilities in a multi‐step process known as tumorigenesis. 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As a whole,  “breast cancer”  is  really a collection of diseases with a wide array of etiologies.  Tumors  arise  from  the  epithelial  cells  of  the  mammary  ducts  (ductal carcinoma) or glands (lobular carcinoma). However, this histological distinction does not correspond  with  the  clinically  important  molecular  subtypes  (10).  Recent  molecular profiling  further  separates  breast  cancers  into  subtypes  based  on  gene  expression signatures.  Cancers of the luminal subtype express hormone receptors and, due to newer targeted  therapies, have a generally good prognosis.  In contrast, basal  type  tumors  lack estrogen  and  progesterone  hormone  receptors,  making  them  refractory  to  popular targeted  therapies.  This  combined  with  the  higher  rate  of  aggressiveness  and invasiveness  associated  with  basal  tumors  leads  to  a  generally  poor  prognosis  (10). Overlapping this basal subtype are the “triple‐negative” cancers, which lack the estrogen and  progesterone  receptors  (ER  and  PR,  respectively)  as well  as  the  human  epidermal growth  factor  2  (HER2/neu/ErbB2),  and  are  currently  the  subject  of  intense  research. Identification  of  this  three‐gene  signature  is  clinically  important  in  assigning  therapy regimens,  although  some  studies  now  suggest  an  expansion  to  five  genes  with  the inclusion of epidermal growth factor receptor 1 (EGFR) and cytokeratin 5/6 (11). Cancer stem  cell  populations  have  been  identified  in  breast  cancers,  and  these  subtypes might represent tumors arising from stem cells at different stages of differentiation (10).   
1.1.2  Clinical impact of metastatic disease Metastatic  tumors  in  organs  distant  from  the  primary  cancer  account  for  the majority of  breast  cancer deaths.  Fewer  than 5% of patients diagnosed with metastatic breast cancer achieve complete remission (12).  Early‐stage, non‐invasive breast cancers, or  ductal  carcinoma  in  situ  (DCIS),  are  diagnosed  in  nearly  50,000 women  every  year, with  approximately  30%  of  these  patients  presenting  with  invasive  disease  in  the ipsilateral  breast  within  the  next  6  to  10  years  (12).    Identification  of  biomarkers  to predict  the  occurrence  of  invasive  disease  would  have  a  profound  impact  on  the treatment  of  these  patients.  Additionally,  treatment  plans  for  women  diagnosed  with locally  invasive  disease  could  be  tailored  based  on  these  markers,  advising  whether localized  radiation  or  systemic  therapy  is  more  suitable.  These  methods  would  spare 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many patients from the unnecessary toxicity of systemic chemotherapies and target only the  most  high‐risk  patients  with  aggressive  treatments.  Furthermore,  identification  of pro‐invasive pathways also presents novel targets for the development of anti‐metastatic therapies best suited to these early‐stage and locally invasive subtypes.  
 
1.1.3   EGFR and HER2 oncogenesis in breast cancer Oncogenes  are mutated  genes  that  promote  tumorigenesis.  In  breast  cancer,  the family of ErbB receptor tyrosine kinases (RTKs) are potent oncogenes whose expression in  tumors  inversely  correlates with  the  clinical  prognosis  (13).    The  epidermal  growth factor  receptor  (EGFR/HER­1/ErbB1)  is  activated by  its  ligand, EGF    (as well  as TGFα, HB‐EGF,  amphiregulin,  and  others)  upon  which  it  dimerizes  and  becomes phosphorylated. Active EGFR dimers trigger downstream signaling pathways with a wide range  of  outcomes,  including  proliferation,  survival,  and  migration.  Classically,  EGFR activates  the  PI‐3K/Akt  and  Ras/Raf/MAPK  pathways.  Activation  of  Akt  leads  to  cell survival via phosphorylation and inhibition of the pro‐apoptotic Bcl‐2 family of proteins and cell  cycle arrest  through  inactivation of  the p21 and p27 cell  cycle  inhibitors. EGFR can  also  activate  the  STAT  family  of  transcription  factors,  specifically  STAT3  in  breast cancer,  promoting  transcription  of  genes  for  proliferation  (c‐myc)  and  cell‐cycle progression  (p21  and  cyclin  D1)  (14).  In  addition  to  the  classical  signaling  cascades resulting from EGFR activation, EGFR can also translocate to the nucleus to act directly as a  transcriptional  regulator  (14). Overexpression as well  as  the appearance of  activating mutations in EGFR has been identified in a variety of cancers, leading to the development of  several  EGFR‐targeted  inhibitors.  Specific  small molecule  inhibitors  of  EGFR,  such  as gefinitb  (Iressa®;  AstraZeneca)  and  erlotinib  (Tarceva®;  Genentech)  are  approved  for treatment  of  lung  and  metastatic  colorectal  cancers,  but  have  shown  only  moderate effects in various trials for breast cancer.   The  second  member  of  the  ErbB  family,  HER2/neu  (ErbB2)  has  no  identified ligand, but is activated by heterodimerization with other family members. Functioning as a  co‐receptor  with  the  other  ErbB  receptors,  many  of  the  transformative  signaling 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pathways  activated  by  EGFR  are  also  activated  by HER2.    However,  ligand  dissociation rates  from  HER2‐containing  heterodimers  are  slower  than  without  HER2,  leading  to prolonged ErbB signaling (15). Amplification and/or overexpression, which occur almost entirely  in  ductal  carcinomas,  are  found  in  approximately  20‐30%  of  invasive  breast cancers  (16,  17).  Activating  mutations  may  also  be  present  which  lead  to  constitutive activation.    Overexpression  of  HER‐2/neu  is  associated  with  more  aggressive  disease, faster proliferation, and decreased sensitivity to chemotherapy. Anti‐HER2 therapies such as  trastuzumab  (Herceptin®;  Genentech)  have  had  high  rates  of  success  in  HER2‐overexpressing cancers.    




Many  cellular  functions,  including  maintenance  of  cell  shape,  polarity,  division, adhesion, intracellular trafficking, and motility are dependent on the cytoskeletal system. The cytoskeleton can  translate  cues  from  the extracellular environment  into changes  in gene  expression  and  differentiation.  The  structural  and  regulatory  components  of  the cytoskeleton are highly conserved across all organisms, attesting to its importance in the most basic cellular  functions.     Because  the cytoskeleton utilizes a system of multimeric filaments,  it  can  rapidly  respond  to  changing  extracellular  cues  to  change  shape  by rearranging  the  building  block  subunits.  Migrating  cells  generate  discrete  structural organelles,  such  as  lamellipodia,  podosomes,  and  invadopodia, which  are  driven  by  the force  of  elongating  cytoskeletal  filaments.  Many  accessory  proteins  participate  in  the regulation of filament dynamics, linking the intracellular signaling to a functional output (41‐44).  In  addition  to  providing  the  mechanical  drive  for  cellular  migration,  the  actin cytoskeleton  also  provides  the  forces  required  for  endocytosis,  pathogen  invasion, cytokinesis,  and  organelle  transport  within  the  cell.  Studies  of  actin  “comets”  used  for propulsion  by  invasive Listeria  in mammalian  cells  have  provided  excellent models  for investigating the molecular requirements of actin filament polymerization (45).  
 
1.2.1 Actin filament structure and dynamics The  actin  cytoskeleton,  like  the  microtubules,  is  a  dynamic  system  of  small, diffusible subunits that self‐assemble into polarized filaments with a dynamic (plus) end. Individual  chains  are  then  cross‐linked  by  accessory  proteins  into  larger  structures  to create specialized mechanical or functional organelles (41, 43, 45). Components:  Actin  filaments  (microfilaments)  are  2‐stranded,  helical  filaments built from globular actin monomers (G‐actin). These are the thinnest and most flexible of the cytoskeletal filaments, with a diameter of approximately 5‐9 nm. Actin filaments not only provide tracks for intracellular trafficking, but also are critical in the force generation required  for  cellular  motility  and  shape  change.  Each  actin  monomer  added  to  the filament is bound to a molecule of ATP, which is hydrolyzed by the enzymatic G‐actin after 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its  incorporation.  Filamentous  actin  (F‐actin)  is  dispersed  throughout  the  cell,  but  is highly concentrated at the cortex, a region just below the plasma membrane, allowing for rapid  formation  of  migratory  protrusions  at  the  cell  surface.  Traditionally,  the  more dynamic plus end has been termed the “barbed” end and the more stable, minus end the “pointed” end (41, 43, 45). Kinetics: Filament  formation occurs  in  three main phases: nucleation, elongation, and steady state. Although subunits will self‐assemble spontaneously, small oligomers are highly unstable and will dissociate before elongation can proceed. This initial “seeding” of the nascent filament is the rate‐limiting step or “lag‐phase”.  Once  successful  nucleation  has  occurred,  subunits  will  rapidly  assemble  in  the “growth‐phase.” The  filament will  continue  to elongate until  it  reaches  the  “equilibrium phase,”  a  steady  state  in  which  subunits  will  continue  to  assemble  and  disassemble without  changing  the  length  of  the  filament.  In  a  phenomenon  known  as  treadmilling, subunits are added and progress through a filament when both ends of the filament are exposed and are in areas of unequal critical concentrations, allowing subunit addition at one  end  at  the  same  rate  at which  the  opposite  end  is  losing  subunits.  This  activity  is important to the dynamic responsiveness of the actin network. In response to a stimulus, a  small  shift  in  the  rates  of  association  or  dissociation  can  produce  a  rapid  change  in filament length. By coupling spontaneous assembling filaments to the plasma membrane, cells  have  developed  a  method  of  using  very  little  energy  to  accomplish  energetically unfavorable mechanical work (41, 45). 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Nucleation:  Spontaneous  nucleation  of  nascent  filaments  is  a  slow  process,  but  can  be facilitated  by  accessory  proteins  (Figure  1).  There  are  three  primary  proteins  which promote  actin  nucleation:  the  Arp  complex,  the  formin  proteins,  and  spire.  Formins, which  include  mDia1  and  mDia2,  dimerize  via  shared  FH2  domains  to  form  a  ring structure  from which  actin  filaments  spontaneously  elongate.  The  formin  ring  remains bound to the growing plus‐end and moves processively, blocking access by other capping proteins. Regulatory inputs by signaling molecules can alter the function of formins at the plus‐end. Spire functions as a single protein that contains four WH2 domains to bind and stabilize  a  tetramer  of  actin  monomers.  After  elongation,  spire  dissociates  from  the filament, but can re‐bind to cross‐link actin filaments with microtubules (42). The best‐characterized nucleator of actin  filaments, however,  is  the Arp complex (Arp 2/3),  an  aggregate of  7 proteins. Arp 2  and Arp 3 are  structurally  similar  to  actin monomers  and  mimic  a  stable  actin  dimer.  Five  structural  Arp  proteins  (ArpC  1‐5) support the pseudo‐dimer. Although the Arp 2/3 complex can promote nucleation freely, actin filaments are often formed from Arp complexes bound to the side of existing actin filaments.  This  model  of  dendritic  nucleation  describes  the  ability  of  Arp  complex  to initiate  new  branches  of  actin  that  protrude  off  the  mother  filament  at  a  70o  angle, 
Figure  1:  Arp2/3  complex  promotes  actin  polymerization 
through  dendritic  nucleation.  Arp2/3  complex  of  proteins 
facilitates  nucleation  of  nascent  actin  filament,  resulting  in  a 
branched actin structure with filaments at 70‐degree angles. 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forming  web‐like  networks.  In  migrating  cells,  this  multi‐directional  polymerization allows the cell to more quickly respond to extracellular cues and “steer” in any direction by altering the localized activation state of the Arp complex (41‐44, 46, 47).  Organization  of  individual  filaments  into  larger  structures  requires  cross‐linking accessory proteins. Actin  filaments  can be  arranged  in  to  either bundles of  closely  tied, parallel  fibers  or  looser webs  of  short  filaments with more  flexibility.  Stress  fibers  are contractile actin bundles linked together by alpha‐actinin and myosin to provide tension between  the  cytoskeleton  and  anchoring  focal  adhesions.  Web‐like  networks  of  actin interlink  short  actin  filaments  at  right  angles  to  provide  a  flexible  rigidity  to  the  cell periphery. Filamin‐actin networks are found in lamellipodia and are required to maintain a migratory phenotype (41‐44, 46).  These  actin  structures must be  tied  to  the plasma membrane  for  effective  shape change.  This  function  is  provided  by  the  ERM  family  of  proteins,  named  for  the  three charter members:  ezrin,  radixin,  and moesin. These proteins  contain a  conserved actin‐binding  C‐terminus  and  an  N‐terminal  domain  that  anchors  to  transmembrane glycoproteins.  Commonly,  this  is  CD44,  the  receptor  for  the  extracellular  matrix component  hyaluronan.  ERM  proteins  exist  in  2  conformations,  open  and  closed, depending on intracellular cues. Elevated levels of PIP2 open the conformation, permitting oligomerization  and  cross‐linking  (41‐44,  46).    Membrane  associated  proteins  are discussed in more detail in section 1.5.2. 
 
1.2.2 Cytoskeletal structures of motility  Cellular migration and invasion are critical to the development and survival of any organism. During  embryogenesis,  cells migrate,  individually  and  as  epithelial  sheets,  as they  differentiate  into  new  tissues.  Notably,  individual  neural  crest  cells  migrate  long distances  along  the  neural  tube  to  colonize  a wide  variety  of  cell  types  in  vertebrates. Gastrulation,  the  process  in  which  the  three  embryonic  germ  layers  are  positioned, requires sheets of cells to move in a coordinated fashion.  But these cell migrations are not limited to development; there are many motile cells that maintain the adult body as well. 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Lymphocytes  such  as  macrophages  and  neutrophils  must  home  to  sites  of  bacterial invasion, osteoclasts and osteoblasts crawl through bone, degrading and replacing tissue, and  fibroblasts  roam  the  stroma  remodeling  collagen  networks.  With  the  singular exception of swimming sperm, all motile cells in the human body migrate by crawling, a process  which  requires  a  dynamic  and  responsive  network  of  sensors,  signaling molecules, and structural filaments (41, 44, 48). While  the protrusive  force  at  the  leading  edge of  a migrating  cell  is  provided by elongation  of  actin  filaments,  the  microtubule  network  is  also  critical  for  efficient  cell movement. Polarity is a pre‐requisite for directional migration, and microtubules provide the  asymmetric  network  that  reorients  the  Golgi  towards  the  leading  edge.  While disruption  of  microtubules  does  not  impair  the  formation  of  protrusions,  their distribution  is  scattered  and  does  not  result  in  a  net  directional migration.  This  is  the result of lost polarity in signaling pathways and intracellular trafficking. Cdc42 activation not  only  controls  actin  polymerization,  but  also  induces  microtubule  polarity  and centrosome  reorientation  through  the  Par6/aPKC  (atypical  protein  kinase  C)  complex (49, 50).   Microtubules,  as well  as  intermediate  filaments,  contribute  to  the  turnover of adhesions, which is necessary for cellular migration. 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Specialized  structural  organelles  are  formed  by  both  motile  and  non‐motile  cells  to interact with the surrounding environment (Figure 2). Microvilli are short protrusions of bundled actin from the apical face of absorptive epithelial cells in the gut, which greatly increase  the  available  cell  surface.  Villin  cross‐linking  is  specific  to microvilli.  Crawling cells utilize a variety of specialized structural organelles to sense their environment and 
Figure  2:  Cytoskeletal  structures  of  motility.  A)  Three‐dimensional  rendering  of  a  cell  as  it 
migrates across and invades a matrix‐like substrate. The lamellipodium, which is enriched in highly 
branched  actin  filaments,  is  at  the  leading  edge  of  the  cell.  From  the  lamellipodium  emerge 
filopodia,  sensory  structures  of  bundled  actin.  Contractile  stress  fibers  terminate  at  focal 
adhesions, which are being dissolved at the trailing edge of the cell.  Invadopodia, also formed of 
bundled  actin,  emanate  from  the  ventral  face  of  the  cell  to  invade  and  degrade  the  gelatin 
substrate. B)  Higher‐magnification  view of  an  active  invadopodia  as  it  degrades  a  layer  of  FITC‐




locomote forward (Figure 2). The initial phase of migration requires forward protrusion, driven  by  polymerization  and  re‐organization  of  actin  into  uni‐  or  multi‐dimensional arrangements. Along the leading edge of a migrating cell, a broad, flat extension known a 
lamellipodium  expands  out  parallel  to  the  substrate  and  adheres  to  propel  the  cell forward.  These  structures  have  been  well  studied  in  frog  and  fish  keratocytes, demonstrating  the  dendritic  nucleation  model  of  Arp2/3‐mediated  actin  branching. Microinjection  of  fluorescent‐actin  into  these  structures  has  demonstrated  array treadmilling,  in which  the  filaments  turnover within  the  network  (51).  Just  behind  the branched actin of the lamellipodium, resides a more stable, progressive lamellum. Ruffles are  similar  sheet‐like  protrusions  of  the  membrane,  but  are  distinguished  from lamellipodia  by  their  lack  of  substrate  adhesion,  resulting  in  migration  of  the  ruffle rearward up  the dorsal  surface of  the cell  (42). Whereas  lamellipodia provide  the main thrust  of  migration,  filopodia  serve  as  “directional  sensors”  to  sense  the  extracellular environment  at  the  far  leading  edge.  Filopodia  are  thin  (less  than  200nm  in  diameter), finger‐like  projections  of  bundled  actin  that  are  extended  by migrating  fibroblasts  and neural growth cones.  Three‐dimensional actin growth at  the  leading edge creates pseudopodia, which are  short  protrusions  seen primarily  in  amoebae  and neutrophils.    Adhesive  structures anchoring  the  migrating  cell  to  the  underlying  substrate  must  also  be  dynamic;  new adhesions  must  be  established  at  the  leading  edge  of  the  lamellipodium  while  older adhesions  along  the  rear  of  the  cell  must  be  broken  for  retraction  of  the  cell  body. Protruding lamellipodia that fail to adhere are swept up on the dorsal face of the cell as membrane ruffles and carried back to the cell body. Focal adhesions link the extracellular matrix to the stress fibers of the actin cytoskeleton via transmembrane integrins.  Sensing the substrate and tensions, integrins cluster and activate the focal adhesion kinase (FAK) via  Src  (tyrosine  kinase).  This  signaling  pathway  is  critical  for  cell  survival,  growth, proliferation, and migration (43, 52, 53). 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Some adult cells must invade tissues to perform their normal functions. These cells have  developed  specialized  cytoskeletal  structures  to  facilitate  their  unique method  of migration. Podosomes  are  finger‐like  extensions  found  on  the  basal  surface  of  the  cell that mediate adhesion to the extracellular substrate via integrins. Podosomes are built of a  central  core  of  bundled  F‐actin  around  which  lies  a  characteristic  ring  of  accessory proteins  that  includes  adhesion‐related  proteins  such  as  integrins  and  vinculin.  Also within the actin‐dense core are actin‐regulators such as (N‐)WASp and Arp2/3. Cortactin is  also  present  in  podosomes,  possibly  acting  as  a  scaffolding  protein  for  N‐WASp  and Arp2/3 (54). Whereas podosomes are described primarily in monocyte‐derived cells such as  macrophages  and  osteoclasts,  similar  structures  known  as  invadopodia  have  been described in Src‐transformed fibroblasts and cancer cells (Table 1) (41, 42, 44, 54‐58).   
Table 1: Comparison of podosomes and  invadopodia. Despite  sharing many of 
the  same  components,  podosomes  and  invadopodia  are  differentiated  by  their 
size, behavior, and the cells in which they are found. 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1.2.3 Structure and signaling of invadopodia  The  terms  podosome  and  invadopodium  have  been  used  interchangeably  in reference to protrusive structures  formed by Src‐transformed fibroblasts (59‐61). Some reports  have  speculated  podosomes  to  be  precursors  to  invadopodia,  although  no evidence  has  been  found  to  support  this  theory.  Others  argue  them  to  be  distinct organelles,  dependent  on  the  cell  type  or  extracellular  environment.  Invadopodia  are typically much  larger,  longer‐lived,  and  fewer  in  number.  Both  are  enriched  in matrix‐metalloproteases,  specialized  proteins  for  ECM  degradation,  although  invadopodia  are much more capable of degrading matrix  (Figure 3)  (41, 42, 44, 54‐58, 62, 63). Table 1 summarizes the common features and differences between podosomes and invadopodia (54). 
Figure 3: Formation of invadopodia over gelatin substrate. A) Formation of invadopodia 
by breast cancer cell grown on FITC‐fibronectin substrate Reprinted with kind permission 
from  Springer  Science+Business  Media:  Clinical  and  Experimental  Metastasis, 
Invadopodia:  specialized  cell  structures  for  cancer  invasion,  23,  2006,  97‐105,  A.M. 
Weaver,  Figure 1. B)  Electron micrograph of  invadopodia  invading gelatin  layer  from a 





  Although the membrane protrusion of invadopodia is driven by bundled actin, this structure is dependent on a base of branched actin similar to the actin structures found in lamellipodia.  Because  of  their  similar  structures,  it’s  no  surprise  that  podosomes  and invadopodia would share many of the same actin regulatory proteins,  including Arp2/3, N‐WASp, cortactin, cofilin, and dynamin‐2.  In addition to cortactin and N‐WASp, several other Src‐targeted proteins, like FAK, p130Cas, and Tks5/FISH, are also common to both (54,  58).  A  high  concentration  of  phospho‐tyrosine  is  found  in  invadopodia  (64), suggesting elevated Src activity.  In  the dynamic podosomes, microtubules are critical  to their  rapid  turnover  and  patterning.  The more  stable  nature  of  invadopodia,  however, limits  their  reliance  on  the microtubule  network  for  formation.  Intracellular  trafficking along  microtubule  networks  may  be  necessary  for  delivery  of  proteinases  for  matrix degradation (53, 54). Cortactin: The role of cortactin in invadopodia formation has been studied in more detail  and  is  required  for  the  early‐stages  of  formation  (56,  65,  66).  Studies  have implicated  cortactin  as  a  central  scaffolding  protein  that  brings  together  many  of  the proteins required  for  invadopodia maturation (55, 56, 65, 67, 68). Cortactin,  in synergy with N‐WASp, potentiates Arp2/3 activation and stabilizes Arp2/3‐dependent branched actin structures (69). More recently, Clark et al also demonstrated a role for cortactin in targeting the metalloproteases MMP2 and MMP9 for secretion (56).  Cdc42/NWASp:  Overexpression  of  components  of  this  pathway,  including  Cdc42  and Arp2/3  subunits,  has  been  described  in  invasive mammary  tumors  (70).  Using MTLn3 mammary  rat  adenocarcinoma  cells,  Yamaguchi  (68) demonstrated  that  endogenous N‐WASp localizes to invadopodia and is required for invadopodia formation (per siRNA and dominant  negative  experiments).    Using  a  FRET‐based  biosensor,  Lorenz  (71) demonstrated  that  N‐WASP  is  unfolded,  and  therefore  active,  at  the  base  of  nascent invadopodia.    Other  WASP  family  members  WAVE1  and  WAVE2  do  not  localize  to invadopodia  (68).  Nck1,  an  upstream  activator  of  N‐WASp,  and  WIP,  the  WASP‐interacting protein which binds and stabilizes (N‐)WASp, also concentrate at invadopodia 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and are required  for  their  formation (68). Active, GTP‐bound Cdc42  is also required  for invadopodium formation (68).    In  cultured  cells,  invadopodia  are  routinely  identified  by  co‐localization  of degraded  substrate  with  actin  and  cortactin.  Similarly,  N‐WASP  and  Cdc42  are  co‐localized with invadopodia (54, 55, 65, 68, 71). EGFR:  EGF  stimulation  promotes  the  formation  of  invadopodia,  presumably through  this  Cdc42‐N‐WASP  pathway  (Figure  4)  (68,  71).  EGF  stimulation  of  cells 
Figure  4:  Signaling  pathways  of  invadopodia  formation.    The  WIP‐NWASp  complex  is 




expressing an N‐WASp biosensor elicits a spike in N‐WASp activation at the cell periphery in  response  to  EGF  stimulus  (71).  Inhibition  of  EGFR  (using  AG1478)  decreased invadopodia  formation  in rat mammary adenocarcinoma cells (68). This correlates with previous  studies  showing  that  EGFR  inhibitors  block  invasion  of  cancer  cells  (72,  73). Most  recently,  DesMarais  et  al  demonstrated  that  cells  preferentially  form  early  stage invadopodia on the side closest to an EGF source (74). ECM remodeling: In addition to becoming motile, invading cancer cells also acquire the  ability  to  break  through  the  basement  membrane  separating  the  tumor  from  the endothelial  cells  of  nearby  blood  vessels.  Invadopodia  are  also  sites  of  concentrated protease  secretion,  allowing  them  to  degrade  the  extracellular  matrix  and  facilitate cellular migration  through  a  basement membrane  (55,  68,  75,  76).  ECM degradation  is mediated  by  matrix‐metalloproteases  and  both  transmembrane  proteases  (MT1‐MMP and seprase) and secreted proteinases  (MMP2 and MMP9) are enriched at  invadopodia (56).  






The  first  form  of  Src  (v‐src)  was  identified  as  the  virally‐encoded  transforming gene responsible for chicken sarcomas. Peyton Rous isolated the causative virus in 1911 from  filtered  fluids  extracted  from  the  tumors  and  demonstrated  the  induction  of  new tumors in healthy chickens injected with the virus. Infection of cultured cells also induced transformation,  leading  to  the  search  for  the  oncogenic  mechanism  of  the  virus,  now called Rous sarcoma virus (RSV). By 1977, the encoded v‐Src protein was isolated by Joan Brugge  and  Ray  Erikson,  the  first  and  one  of  the  most  potent  oncogenes  identified. Transfection of v‐Src  into cultured cells  induces shifts  in gene expression, alters cellular morphology and adhesion, and increases migration.     Research by Michael Bishop and Harold Varmus identified a cellular form, dubbed c‐Src,  in normal chicken cells. This normal version of Src, homologs of which have been identified  in  nearly  every  species,  is  known  as  a  proto‐oncogene,  the  non‐mutated precursor of an oncogene. Src was also the  first  tyrosine kinase to be characterized and functions in a wide variety of signal transduction pathways.  Under normal conditions, c‐Src  is non‐transforming. However, activating mutations  in c‐Src can shift  the regulatory balance  and  induce  some  hallmarks  of  transformation  such  as  anchorage‐  and  growth factor‐independent  growth.  The  potent  transforming  effects  of  v‐src  demonstrate  the need  for  tight  regulation  of  this  kinase  in  normal  cells.  Therefore,  much  subsequent research focused on the comparative structure and regulation of the v‐ and c‐Src kinases (79).    
1.3.2 Structure and regulation of Src  The regulation of Src is dependent on its structure, which is comprised 2 protein‐interaction domains, SH2 and SH3, and a catalytic domain (Figure 5). Activity of normal c‐Src  is  tightly  regulated  through  the  auto‐inhibitory  folding  that  results  from  the intramolecular interaction between the short, regulatory domain at the carboxyl terminus and  the  internal  SH2  domain.  This  conformation  is  controlled  by  the  balance  of  two tyrosine  phosphorylation  sites:  Tyr416  (Tyr419  in  human  Src)  and  Tyr527  (Tyr530  in human Src). Phosphorylation of Tyr527/530 in the regulatory domain by Csk (C‐terminal Src  kinase)  inactivates  Src  by maintaining  the  auto‐inhibitory  interaction with  the  SH2 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domain. An additional intramolecular interaction between the SH3 domain and the short linker  region  between  the  SH2  and  catalytic  domains  further  strengthens  the  closed conformation. Tyr416/419  in  the kinase domain  is  auto‐phosphorylated  in active,  open Src.  An analogous tyrosine residue is found within the activation loop of all other tyrosine kinases. The constitutive activity of v‐Src results from the loss this tight regulation due to the deletion of the regulatory domain, keeping Src in the open, active conformation.  






1.3.3 Src and cytoskeletal reorganization The  tyrosine  kinase  function  of  Src  is  involved  in  many  signaling  pathways, including  those  that control  the cytoskeleton (Figure 6). The cytoskeleton plays a  large role  in modulating  the activity of Src.  Intracellular  localization of Src correlates with  its activation  state.  Inactive  Src  is  sequestered  at  the  perinuclear  region  of  the  cell  in
Figure 6: Src‐dependent signaling pathways. Src activity is critical to many signaling pathways, leading 
to  a  wide  variety  of  cellular  functions,  including  mitogenesis,  proliferation,  survival,  angiogenesis, 
apoptosis,  and  actin  reorganization.  Active  growth  factor  receptors,  such  as  EGFR,  promote  Src 
activation.  Src may also be activated in complexes with FAK downstream of integrins. 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association with the microtubule network. However, active Src translocates to the plasma membrane where it associates with actin via the SH3 domain. Myristilation at the amino‐terminus also  interacts with  the plasma membrane. This  translocation  is not dependent on  an  intact  Src  kinase  domain  (80).  Src  is  recruited  to  focal  adhesions  through  its interaction with the Focal‐adhesion kinase (FAK), which stabilizes the open conformation of Src and encourages Src activity. The FAK‐associated adaptor protein p130CAS may play a  similar  role  (81).  Src‐null  fibroblasts and osteoclasts have severe cytoskeletal defects, including lost adhesion and rounding. These phenotypes can be rescued even by kinase‐deficient  Src  mutants,  indicating  a  kinase‐independent  role  for  Src  in  maintaining  the cytoskeleton.  However, rescue of migratory defects does require the activity of Src at the plasma  membrane  and  at  focal  adhesions  (82).  Phosphorylation  of  Src‐targets  at peripheral adhesion sites, such as FAK and p190rho‐GAP, is necessary for focal‐adhesion turnover, a pre‐requisite of cellular migration. Fibroblast that are deficient in either FAK or  Src  are  non‐motile  and  have  enlarged  adhesions,  presumably  due  to  lost  turn‐over (81).  FAK  is  also  capable  of  phosphorylating  N‐WASp  at  Tyr256  leading  to  actin nucleation through the Arp2/3 complex (83).  Additionally, cells that are lacking a kinase‐competent Src are unable to polarize towards a chemoattractant (81). Src also phosphorylates the actin cross‐linking protein cortactin, which stabilizes Arp2/3‐mediated  actin  assembly  (81).  Src  phosphorylation  of  cortactin  decreases  its ability to bind actin, leading to impaired cytoskeletal rearrangement (84). Recent studies of cortactin have demonstrated its central role in the organization of specialized invasive structures (56, 65, 66). 
 
1.4 CELLULAR REGULATION OF CDC42 AND N­WASP ACTIVITY  
1.4.1 Rho GTPases The Rho family of GTPases  is a subset of  the  larger Ras family of proteins, which function  as  integration  points  for  the  control  of  cytoskeletal  regulatory  proteins.  Rho GTPases  are  important  in many  cellular  functions,  including  cell  cycle  progression,  cell division,  cell  polarity,  and migration.  (Reviewed  by  (85)  and  (86)).  Although  there  are 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over  20  known  members  of  the  Rho  GTPase  family,  there  are  three  that  are  well characterized:  Cdc42  (cell  division  cycle  42),  Rac1  (Ras‐related  C3  botulinum  toxin substrate  1),  and  RhoA  (Ras  homologous  member  A).    These  molecular  switches  are downstream  of  several  different  G‐protein  coupled  receptors  and  receptor  tyrosine kinases (87)   Switching mechanism of small GTPases. GTPases exist  in  two states:  the  inactive, GDP‐bound state and  the active, GTP‐bound state.  In  the active state, GTPases bind and regulate  effector  proteins.  Upon  hydrolysis  of  the  bound  GTP  molecule,  the  GTPases revert  to  an  inactive  conformation.  Although  GTPases  possess  the  intrinsic  ability  to hydrolyze  GTP,  specific  GTPase‐activating  proteins  (GAPs)  promote  GTPase  hydrolytic activity  and  subsequent  inactivation. Alternatively,  guanine nucleotide  exchange  factors (GEFs)  catalyze  the opposite  reaction,  in which a GDP molecule  is  exchanged  for  a GTP molecule to activate the GTPase again. Activation of small GTPases is blocked by guanine nucleotide dissociation inhibitors (GDIs), which sequester GDP‐bound forms of the small G  proteins  in  the  cytosol.  Constitutively  active  GTPase  mutants  impair  the  hydrolytic activity of the GTPases, thereby locking them in the GTP‐bound state (85, 86, 88).  Rho  GTPase  activation  induces  a  variety  of  cellular  behaviors,  including transcriptional  regulation  and  cell  cycle  progression.  Cytoskeletal  reorganization  for polarity and migration are heavily dependent on the regulation provided by RhoGTPases.  
 
1.4.2 Cdc42 Functions and Effector Proteins  Polarity Polarization is fundamental to many cellular processes, including division, secretion,  and migration,  and  is  typically dependent on external  signals. Polarity  is  also established by localized recruitment of Cdc42 to activated receptors, as well as activated cell  adhesion  molecules  (89).  Cell‐cell  contact  activates  Cdc42  through  nectin  and  E‐cadherin  leading  to  generation  of  apical  and  baso‐lateral  surfaces  (90).  Cdc42  is  also critical  to  the polarization of T cells  towards  the  immunological  synapse  formed during interaction with an antigen‐presenting cell. Upon activation of the T‐cell receptor, Cdc42 and its effector protein WASP are recruited to promote localized actin polymerization and 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generation of the synapse. Additionally, the MTOC and Golgi are re‐oriented towards the synapse  for  the  delivery  of  secretory  vesicles,  a  process  that  is  dependent  on  Cdc42 activity  (89).  Chemotactic  cells  also  polarize  in  a  similar  manner  to  soluble  factors. Chemokines  such  as  EGF  and  PDGF  bind  and  activate  cell  surface  receptors,  recruiting Cdc42  to  the  plasma membrane  and  activating  Cdc42  via  the  Src  pathway  (91‐93).  For motile cells,  the  initial step  in mesenchymal‐type migration  is polarization  to define  the regions  of  protrusion  at  the  leading  edge  and  retraction  of  the  cell  body  at  the  trailing edge.  Migration  Active,  GTP‐bound  Rac  accumulates  at  the  leading  edge  of  migrating cells  and  establishes  a  positive‐feedback  loop  between  PIP3  and  PI3‐kinase  (63). Activation of PI3K results in increased PIP3 at the plasma membrane and activation of Rac and Cdc42.  In advancing  lamellipodia, Rac  induces actin polymerization via  the effector protein WAVE and activation of the Arp complex. Rac can also activate the LIM‐kinase in lamellipodia  to  phosphorylate  and  inhibit  cofilin  activity  effectively  stabilizing  actin filaments. Downstream of Rac and Cdc42, the cross‐linking protein IQGAP may function to stabilize  the  actin  meshwork.  Although  Cdc42  is  not  required  for  formation  of lamellipodia, it does contribute to the protrusion of filopodia from the leading edge. This occurs  through  the  activation  of  the  Cdc42  effector  protein,  N‐WASp,  a  promoter  of Arp2/3 activation and actin polymerization. Rho functions primarily in contractile forces filaments and also participates in lamellipodia activity in hepatocyte growth factor (HGF)‐stimulated KB cells. Interestingly, there is also complex cross talk between Rho, Rac, and Cdc42.  In  general,  the  cell  body  retraction  at  the  rear  of  the  cell  is  dependent  on  Rho signaling  through  ROCK  and  MLC  phosphorylation  to  create  actin‐myosin  contractile bundles (42, 86, 88). Effector proteins Active GTPases mediate  their responses  through a wide variety of effector proteins. Many of these proteins have been identified through yeast 2‐hybrid screens and contain the classical Cdc42/Rac‐interactive binding (CRIB) domain. Rac and Cdc42 share many of  the same targets, such as IQGAP and PAK1‐3, which mediate actin reorganization, cell‐cell adhesion, and stress‐fiber formation. Cdc42 plays a unique role in 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filopodia and  invadopodia  formation  through  its effects on  the WASP/N‐WASP proteins (85, 88).   
   
1.4.3 N­WASP Family and Regulation WASP  family  Wiskott‐Aldrich  Syndrome  (WAS)  is  a  rare,  X‐linked  disorder characterized  by  eczema,  thrombocytopenia,  and  immunodeficiency.  Mutations  in  the gene for the WAS protein (WASP) typically result in premature truncation of the protein, leading  to severe platelet and  immune system defects. WASP expression  is restricted  to hematopoietic  cells,  while  the  closely  related  neural‐WASP  (N‐WASP)  is  ubiquitously expressed.  Another  related  set  of  proteins  was  named  the  WASP  family  verprolin homologous  protein  (WAVE)  1‐3,  also  known  as  SCAR1‐3  (suppresses  abnormalities  of cAR  loss)  (94,  95).  N‐WASP was  the  first  to  be  linked with  actin  polymerization  as  an intermediate effector between Cdc42 and Arp2/3 (96).  
Conserved across the five family members (WASP, N‐WASP, WAVE1‐3) is the C‐terminal 
Figure  7:  N‐WASp  structure  and  regulation.  Intramolecular  interaction  between  the 
connecting  regions  (C) and  the GTPase‐binding domain  (GBD) maintain N‐WASp  in a closed, 
inactive  state.  Cdc42  and  PI(4,5)P2  cooperatively  relieve  the  inhibitory  conformation, 
activating N‐WASp. Open N‐WASp, which  is  accessible  to phosphorylation by  Src,  is  able  to 
activate Arp2/3 and induce actin polymerization. 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WCA domain  (Figure 7). This  is actually a  collection of  three distinct  regions,  the WH2 (W)  domain,  a  connecting  region  (C),  and  the  acidic  domain  (A).  N‐WASP  is  the  only family  member  that  varies  from  this  organization  by  having  a  second  WH2  domain, although  its  function  is  unknown.  The WH2  domain,  in  close  proximity  to  the  Arp2/3 binding site within the acidic A region, binds actin monomers. The connecting (C) region is  responsible  for  the auto‐inhibitory  folding conformation by binding  to a central CRIB domain. Binding of active Cdc42 to the CRIB (also known as GBD, GTPase binding domain) displaces the C region, opening and activating N‐WASP (95, 97). Once open, N‐WASP can bind Arp2/3, increasing Arp2/3’s affinity for ATP and promoting actin nucleation (47, 94, 98).  Flanking  the  CRIB  domain  are  poly‐lysine  (BR,  basic  region)  and  poly‐proline domains to which other regulatory proteins and adaptors bind. PI(4,5)P2 binds to the BR and  with  Cdc42  can  synergistically  activate  N‐WASP.  SH3‐containing  adaptor  proteins such  as  Nck2  and  Grb2  bind  the  proline‐rich  region,  presumably  to  link  N‐WASP  to activated  receptor  tyrosine  kinases  (RTKs)  such  as  epidermal  growth  factor  receptor (EGFR).  The  tyrosine  kinases  Src  and  Fyn  also  bind  here,  although  the  function  of  N‐WASP’s  tyrosine  phosphorylation  sites  is  still  not  understood.  N‐WASP may  be  able  to integrate  the  signaling  pathways  of  GTPases with  tyrosine  kinases  in  the  regulation  of actin nucleation (95, 97, 99, 100). The Cdc42‐interacting protein, CIP4, also interacts with N‐WASP through the proline‐rich domain via its own SH3 domain (101, 102). The WASP interacting  protein  (WIP)  binds  to N‐WASP  at  the WH1 domain  and  can  interfere with Cdc42‐mediated  activation  of  N‐WASP  (103).  However,  its  presence  also  seems  to  be required for efficient activation of N‐WASP by Toca‐1 (transducer of Cdc42‐activation‐1) (104,  105).
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Figure 8:  Structure and isoforms of CIP4. A) Domains and protein interactions of human CIP4a. 
Amino  acid  positions  are  shown  below  each  domain.  MGD,  I,  and W  are  conserved  residues 
amongst CIP4 and Toca‐1. Mutations in MGD or I abrogate binding to Cdc42, where as mutation 







1.5.1 Characterization of CIP4   The  Cdc42‐interacting  protein  4  (Figure  8a)  was  originally  identified  through yeast‐2‐hybrid screens for novel binding partners of the RhoGTPase Cdc42 (101), WASP (106), and the Src family kinase Lyn (102). It was immediately characterized by its unique amino‐terminal  coiled‐coil  domain,  which  was  termed  FCH  (FER‐CIP4  homology), analogous  to  the  coiled‐coil  domain  of  the  actin‐associated  protein  Cdc15  in  S.  pombe. Subsequently,  the carboxyl‐terminal SH3 domain was shown to  interact with WASp and mediate  its  binding  to  microtubules  (106).  Interaction  between  CIP4  and  N‐WASp  is necessary  for  podosome  formation  in macrophages  (107).  Alternative  isoforms  of  CIP4 have been identified that lack a functional SH3 domain due to retained intronic sequences near the Cdc42 binding region (Figure 8b) (102, 108, 109).  The HR1 domain, an internal coiled‐coil motif with homology to the protein kinase C, mediates  binding  of  CIP4  to  GTP‐Cdc42,  not  a  classical  Cdc42‐binding  CRIB  domain. Point mutation of  the  isoleucine at 398 within  the HR1 abrogated Cdc42 binding (106). Two proteins closely related to CIP4 have since been identified, namely Formin binding 
protein 17 (FBP17) and transducer of Cdc42 activation 1 (Toca‐1). These proteins share similar  FCH  and  SH3  domains  and  bind  N‐WASp  and  dynamin  via  their  SH3  domains (Figure  9)  (105,  110).  Toca‐1  and  FBP17  also  share  similar  HR1  regions,  however mutation  of  the  analogous  isoleucine  in  Toca‐1  did  not  interrupt  Cdc42  binding,  but required triple mutation of the adjacent MGD sequence (105). FBP17 does not bind Cdc42 (111). Toca‐1 also potentiates the Cdc42‐dependent activation of N‐WASp mediated actin nucleation (105, 110). Functional studies of these proteins are still limited. 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Recently,  our  understanding  of  the  N‐terminal  region  has  evolved  greatly.  Tsujita  et  al demonstrated the weak homology of the coiled‐coil domain to the BAR (Bin‐amphiphysin‐Rvs) family of proteins. Like other members of the BAR family, this structure can induce the tubulation of membranes (112, 113). In tandem, the N‐terminal FCH and BAR regions comprise  the  F‐BAR domain  (also  known  as  EFC  for extended FCH),  a  subgroup  of  the larger  BAR  family  that  is  characterized  by  a  shallower  curvature  (112,  114,  115).  BAR proteins  (lacking  the  FCH)  and  I‐BAR  proteins  (inverse‐BARs)  function  by  the  same mechanism,  but  have  different  degrees  of  curvature,  producing  different  diameters  of membrane tubules (116, 117). 
Figure 9:   F‐BAR family of proteins. Homology of CIP4, Toca‐1, and FBP17 at protein and 
mRNA (parentheses) sequence levels.  Significant conserved residues are noted: MGD and  




1.5.2 BAR Domains and membrane curvature  Effective  cell  shape  change  requires  not  only  the  forces  provided  by  the  actin cytoskeleton,  but  also  molding  of  the  cell  membrane.  Proteins  of  the  BAR  (Bin‐
amphiphysin‐Rvs) superfamily, which are capable of binding and/or inducing membrane curvature,  are  the  convergence  point  for  RhoGTPase  signaling,  actin  remodeling,  and membrane dynamics. The BAR structure that is shared by all members of the superfamily is defined as a coiled‐coil region with a positively charged surface. The 3 repeated alpha‐helices of each domain form a hydrophobic, curved structure (Figure 10) that mediates 
Figure  10:  Ribbon  structure  of  dimerized  BAR  domains.  From  top:  I‐BAR  (IMD/IRSp53), 
BAR/N‐BAR (endophilin), and F‐BAR (CIP4). Bottom diagram indicates individual helices and 
FCH  region  of  F‐BAR  domains.  Reprinted  from  Cell,  129,  K.  Fütterer  and  L.M.  Machesky, 
“Wunder”  F‐BAR  Domains:  Going  from  Pits  to  Vesicles,  655‐657,  Copyright  (2007),  with 
permission from Elsevier. 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dimerization  and  interacts  with  the  negatively‐charged  lipid  membranes,  preferably phosphotidylserine (118).  In most members of the BAR family, this cationic face rests on the  concave  side  of  a  crescent‐shaped  structure.  This  arrangement  is  typical  of  the “classical” BAR and F‐BAR (FCH‐BAR) subfamilies, whereas proteins of the I‐BAR family are inverted with a positively charged convex surface (Figure 10) (112, 114, 115).   The subfamilies of the BAR superfamily are characterized by the degree of curvature created in  the  dimerized  molecule,  which  specializes  the  proteins  to  a  distinct  membrane structure. For instance, the BAR proteins are associated with endocytic vesicles, whereas the  F‐BAR  proteins, which  have  a  shallower  curvature,  are  associated with  the  thinner neck  of  vesicles  as  the  separate  from  the  plasma  membrane  (116,  119).  The  unique inverted  structure of  I‐BAR proteins  is  associated with  the opposite  curvature  found  in membrane protrusions (120, 121). Homologous proteins are conserved in yeast; Cdc15 in fission yeast is found at the contractile acto‐myosin ring as daughter cells separate (122, 123).  Overexpression of BAR domains, either in isolation or within full‐length proteins, is  sufficient  to  induce  membrane  tubulation  (112,  113,  124) However,  some  studies suggest that BAR domains are “curvature sensing” and bind membrane which are already deformed (125). These two arguments are not mutually exclusive: BAR domains binding to curved membranes will be  induced  to dimerize,  recruiting additional BAR‐containing proteins, and in turn inducing additional membrane curvature (116). These mechanisms may also be repeated in caveolae‐dependent endocytosis. Aside  from  their  membrane‐interacting  regions,  BAR  proteins  also  commonly associate  with  the  actin  cytoskeleton  and  cytoskeletal  regulatory  proteins  such  as  N‐WASp/WAVE and dynamin. The interaction between BAR proteins and the cytoskeleton has been best described in clathrin‐mediated endocytosis, specifically in the recruitment of  dynamin  to  promote  membrane  scission  (115,  126,  127).  F‐BAR  proteins  CIP4  and FBP17 both bind N‐WASp and dynamin‐2 via carboxy‐terminal SH3 domains. Toca‐1 and FBP17 are both  inducers of membrane curvature‐dependent actin polymerization  (126, 127). 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1.5.3 TOCA­1 and Actin Polymerization  N‐WASp  activation  is  dependent  on  its  interaction  with  GTP‐Cdc42  and  PIP2 (Figure 7a) (for detailed discussion, see section 1.4.3). Similar to CIP4, Toca‐1 binds GTP‐Cdc42 through the internal HR1 motif and interacts with N‐WASp via the C‐terminal SH3 domain (105). Actin polymerization assays can be used to infer the activation state of N‐WASp  by  quantifying  the  rate  of  pyrene‐actin  assembly  in  cell‐free  systems.  Using  this method,  Ho  et  al  demonstrated  that  depletion  of  Toca‐1  from  xenopus  egg  extracts decreased N‐WASp‐mediated activation of Arp2/3 and actin polymerization (Figure 7b) (105).  Whereas  purified  wild‐type  Toca‐1  rescued  the  phenotype,  mutated  Toca‐1 proteins,  deficient  in  either  N‐WASp  or  Cdc42  binding,  were  unable  to  restore  actin polymerization.  A  constitutively  active  mutant  of  N‐WASp  does  not  require  Toca‐1  to induce  actin  polymerization,  confirming  that  N‐WASp  is  downstream  of  Toca‐1  (105). These  results were  also  repeated by observing  actin  comet  formation on  the  surface of endomembrane vesicles in the presence of Toca‐1 depleted cell extracts (105).  Takano et 
al utilized liposomes to demonstrate that FBP17 and Toca‐1 induce activation of N‐WASp (in  complex  with  WIP)  and  actin  polymerization  that  is  dependent  on  membrane curvature  (127).  Interestingly,  this  effect  was  dependent  on  a  conserved  sequence  of acidic residues adjacent to the SH3 domain, suggesting the conformation of FBP17/Toca‐1 is critical to its function.    
1.6 HYPOTHESIS AND MODEL   F‐BAR  proteins  are  known  to  function  at  the  plasma  membrane  to  sense  and induce  membrane  curvature  through  dimerized  BAR  domains,  amphipathic  crescent shaped  regions  at  the  N‐terminus.  CIP4  and  Toca‐1  also  bind  the  RhoGTPase  Cdc42 through a central HR1 domain and N‐WASp via their c‐terminal SH3 domains.   While F‐BAR proteins have typically been implicated in endocytosis, I propose that there is also a role for the concave‐binding regions of F‐BAR proteins in membrane protrusion. FBP17, which  is  closely  related  to  CIP4  but  unable  to  bind  Cdc42,  contributes  to  podosome formation  in  macrophages  (128).  Toca‐1,  which  is  structurally  very  similar  to  CIP4, stimulates Arp2/3‐mediated actin polymerization through Cdc42‐dependent activation of 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N‐WASp (105). Cell‐free models demonstrated that liposome binding of FBP17 and Toca‐1 increased N‐WASp‐mediated actin polymerization, suggesting a role for F‐BAR proteins in  cytoskeletal  reorganization  at  curved  membranes  (127).  The  study  by  Takano  et  al highlights the importance of an acidic region adjacent to the SH3 domain and presents a model in which this motif repels the lipid bilayer, forcing the SH3 domain away from the plasma membrane  and  the  F‐BAR domain.  Given  the  high  degree  of  similarity  between CIP4  and Toca‐1,  I  propose  that CIP4  functions  in  an  analogous manner. The Corey  lab demonstrated  that Src  family kinases bind and phosphorylate CIP4 at a  site adjacent  to this acidic motif. Therefore, it is likely that Src phosphorylation of CIP4 contributes to the conformation of CIP4 by modulating the electrostatic repulsion. My  preliminary  data  indicates  a  correlation  between  CIP4  expression  and  the invasiveness of breast cancer cell lines in vitro, suggesting that CIP4 might play a role in cellular  motility.  Therefore,  I  propose  a  model  in  which  CIP4  functions  as  a 
scaffolding  protein  that  facilitates  N­WASp  activation  by  stabilizing  the  open 
conformation,  which  increases  its  interaction  with  active  Cdc42  at  areas  of 
membrane  curvature  and  leads  to  localized  actin  polymerization  at  invasive 
cytoskeletal  structures  (Figure  11).  In  this  model,  CIP4  binds  the  lipid  membrane, dimerizes via the F‐BAR domains, and induces membrane curvature. Activation of EGFR and  Src  leads  to  the  phosphorylation  of  CIP4,  strengthening  the  electrostatic  repulsion that forces the SH3 domain away from the membrane and the F‐BAR domain. This spring‐like  conformation  acts  as  a  scaffold  to  maintain  the  open  conformation  of  N‐WASp  by tethering  the  poly‐proline  region  of  N‐WASp  away  from  the  membrane‐bound  basic domain. By stabilizing this open conformation, CIP4 increases access by Cdc42 and Src to the  regulatory  domains  of  N‐WASp,  potentiating  N‐WASp  activation  and  leading  to Arp2/3‐mediated actin polymerization. Through this proposed mechanism, CIP4 targets actin polymerization to areas of membrane curvature, a critical  function  in  invadopodia formation. 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2.1 INTRODUCTION c‐Src  is a non‐receptor tyrosine kinase that  is  involved in many distinct signaling pathways  (Figure 6).  The  structure  of  Src  combines  a  carboxy‐terminal  kinase  domain with SH2 and SH3 interaction domains. This arrangement allows it to function as a kinase within larger, multi‐protein complexes, most notably the FAK‐Src complex. In response to ECM‐interaction, the focal‐adhesion kinase (FAK) is recruited to the cytoplasmic tail of β‐integrins via talin and paxillin. β‐integrins also bind the SH3 domain of Src, encouraging interaction between FAK and Src’s SH2 domain.   FAK auto‐phosphorylation at Tyr397 is associated  with  activation,  although  Src  also  phosphorylates  FAK  at  multiple  tyrosine sites, including Tyr576 in the kinase domain and Tyr925. Paxillin is also phosphorylated by  Src.  The  FAK‐Src  complex  phosphorylates  several  targets  leading  to  increased migration  and  cytoskeletal  rearrangement.  The  p130CAS  (Crk‐associated  substrate) adaptor protein promotes migration after phosphorylation by FAK and Src (20, 33, 129). Also  downstream  of  FAK‐Src  are  Crk  and  the  closely  related  CrkL, which  interact with p130CAS. Activation of CrkL  induces Rac/Cdc42 signaling to promote  integrin dependent migration via WAVE/N‐WASp and Arp2/3 (20).  In  addition  to  the  integrin‐mediated  c‐Src  signaling  through  FAK,  Src  also modulates signaling from receptor tyrosine kinases like EGFR, HER2, PDGFR, and CSF‐1R. Src’s  interaction  and  synergism  with  the  oncogenic  potential  of  EGFR  have  been  well described (33). After EGF‐induced dimerization and transphosphorylation of EGFR, Src is recruited and phosphorylates the cytoplasmic tails of EGFR at Tyr 845 and Tyr1101. This amplifies  the  activation  of  EGFR  targets  such  as  PI‐3K,  Shc,  and MAPK.  PI‐3K  signaling through  the  Akt/IKK/NFκB  cascade  results  in  inhibition  of  apoptosis  via  caspase‐9 inactivation and cell survival. Furthermore, NFκB‐dependent increases in IL‐8 encourage angiogenesis.  c‐Src  encourages  EGFR‐dependent  tumorigenesis  through  potentiation  of signaling.   Given that Src is overexpressed or hyperactive in a variety of human cancers, Src‐targeted therapies have been widely investigated for the treatment of cancers. Several 
  49 
small‐molecule  inhibitors  that  inhibit Src also  inhibit  the Abl  tyrosine kinase due  to  the structural  similarity  between  their  ATP‐binding  domains.  Dasatinib  (BMS‐354825, Sprycel  ®,  [N‐(2‐chloro‐6‐methylphenyl)‐2‐[[6‐[4‐(2‐hydroxyethyl)‐1‐piperazinyl]‐2‐methyl‐4‐pyrimidinyl]amino]‐5‐thiazole‐carboxamide]  is  a  recently  developed  inhibitor of  Src/Abl  that  is  orally  active.    Dual  Src/Abl  inhibitors  like  dasatinib  were  initially approved  for  BCR‐Abl+  leukemias  that  were  refractory  to  imatinib  therapy.  Like  other small‐molecule  inhibitors,  dasatinib  is  capable  of  inhibiting  its  target  at  low concentrations, making it a more favorable clinical option. In vitro  testing demonstrated that  the  kinase  activities  of  Src  and  Abl  are  50%  inhibited  with  less  than  1.0  nM  of dasatinib. Increasing the dasatinib dose leads to inhibition of other tyrosine kinases (p38, Akt, and FAK) and receptor tyrosine kinases (PDGFR, c‐kit, and Ephrin) (130). In lung and prostate  cancer  cell  lines,  low‐dose  (nanomolar)  treatment  with  dasatinib  inhibited proliferation (37, 130‐132). Dasatinib has also shown mixed efficacy in breast cancer cell lines:  “triple‐negative”  cell  lines,  which  lack  ER,  PR,  and  HER2,  are  more  sensitive  to dasatinib  than  other  hormone  receptor‐positive  lines  (133).  However,  the  molecular pathways mediating this selectivity have not been previously been investigated.  
  To  identify  the  molecular  pathways  that  differentiate  dasatinib‐sensitive  from dasatinib‐resistant breast cancer cell lines, I investigated the effects of dasatinib on three cell  lines  that  had  been  previously  screened  for  their  response  to  dasatinib  in  growth assays.  Reliable  measures  of  response  are  an  important  component  in  the  clinical evaluation of tumors treated with targeted therapies. Therefore, I also sought to identify biomarkers  for  dasatinib  response  by  examining  the  inhibition  of  key  Src‐dependent signaling  pathways.  Given  the  critical  role  Src  pathways  play  in  cytoskeletal rearrangement, I evaluated the effects of Src inhibition on the migration and invasion of dasatinib‐sensitive breast cancer cells.    
2.2 MATERIALS AND METHODS 
 
2.2.1 Cell Culture   Breast cancer cell  lines were obtained  from the ATCC via  the  labs of Drs Gordon 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Mills  and  Janet  Price  (MD  Anderson  Cancer  Center,  Houston,  TX).    All  cell  lines  were grown  at  37oC  and  5%  CO2.  MDA‐MB‐231  and  T47D  cells  were  grown  in  DMEM/F12 media  (Invitrogen,  Carlsbad,  CA)  supplemented  with  10%  fetal  calf  serum  (Hyclone, Logan,  UT),  100  U/mL  penicillin,  and  100  μg/mL  streptomycin.  MCF7  cells  were maintained  in  MEM  media  (Invitrogen)  supplemented  with  10%  fetal  calf  serum,  100 U/ml penicillin, 100 mg/ml streptomycin, 2mM L‐glutamine, 0.1mM non‐essential amino acids, 1mM sodium pyruvate, and MEM vitamin solution. 
 
2.2.2 Viability and Proliferation Assays For cell  counting and  trypan blue exclusion,  cells were grown  in  the appropriate media plus dasatinib for up to 72 hours, collected by scraping, diluted in trypan blue dye, and  counted  with  a  Brightline  hemocytometer  (Hausser  Scientific,  Horsham,  PA). Proliferation was determined using an MTT assay (#M5655, Sigma‐Aldrich, St. Louis, MO). Cells were  seeded at  a density  of  3‐5x103  cells  per well  of  96‐well  plate with  complete medium 24  hours  prior  to  treatment.  Cells were  then  treated  for  24,  48,  and  72  hours before MTT reagent was added and absorbance was read at 570nm, per manufacturer’s instructions.  
2.2.3 Statistics and Combination Index Descriptive statistics including mean values and s.d. were calculated using Microsoft Excel or  Prism  software  (GraphPad,  La  Jolla,  CA).  Statistical  significance  was  determined  by two‐sample  student  t‐tests  (P1/40.05).  Calculation  of  GI50  (Dm)  values,  measures  of sigmoidicity (m), correlation coefficients (r), and combination  indices (CI) of multi‐drug treatments were performed using the CalcuSyn software (Biosoft, Cambridge, UK). Degree of cooperation between dasatinib and doxorubicin was determined from the combination index (CI) as follows: CI >1 indicates antagonism; CI = 1 indicates additivity; 1 > CI > 0.3 indicates synergy; 0.3 > CI > 0.1 indicates strong synergy (134, 135).  
2.2.4 Immunoblotting Cells were grown in complete media overnight, treated with dasatinib for 2–48 h, and  washed  in  ice‐cold  PBS.  Whole‐cell  lysates  were  obtained  from  cells  collected  by 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scraping, and  lysed  in 1% NP‐40 buffer supplemented with  the appropriate proteinases and phosphatase inhibitors. Protein concentrations were determined by a Bradford assay and equal amounts of each sample were either prepared for loading by boiling in Laemmli sample  buffer.  Western  blot  analysis  was  performed  with  whole  cell  lysates  or immunoprecipitated  samples  resolved by  SDS–PAGE and  transferred onto  Immobilon‐P Transfer Membranes (Millipore Corp, Billerica, MA, USA). The membranes were blocked overnight  with  blocking  buffer  (5% milk  or  5%  BSA,  depending  on  the  antibody,  with 0.1% Tween‐20). The blots were incubated with primary and then secondary antibodies for 1 h each at  room  temperature.  Immunoreactive bands were visualised by enhanced chemiluminescence (Amersham, Piscataway, NJ, USA). Membranes were then stripped for 30 min at 371C using Stripping buffer (Pierce, Rockford, IL, USA), reblocked, and probed for actin, GAPDH, or  the nonphosphorylated protein being analysed as  loading controls. Densitometric  analysis  was  performed  using  the  NIH  software,  ImageJ  (Macintosh platform, Bethesda, MD, USA),  to determine  the ratio of phosphorylated protein  to  total protein.  For  SrcpY416:  c‐Src,  IC50  values  were  calculated  based  on  exponential regressions of the plotted ratios using Microsoft Excel. For IC50 values of Src  inhibition, ratio  values  of  Src‐pY416  to  total  Src  were  generated  by  exponential  regression (Microsoft Excel). 
 




Cells were grown and treated on glass chamber slides or glass coverslips, fixed in 4% formaldehyde, permeabilized with 0.1% TritonX‐100, blocked in 1% BSA, and stained with  anti‐alpha‐tubulin  (Sigma,  St.  Louis,  MO)  and  Alexa‐488  fluorescent  phalloidin (Molecular  Probes,  Carlsbad,  CA).  Tubulin  staining was  detected with  a  Cy3‐conjugated donkey  anti‐mouse  antibody  (Jackson  ImmunoResearch).  Slides  were  prepared  using ProLong Antifade mounting media (Molecular Probes), and imaged with a Nikon Eclipse TE2000U  microscope  and  MetaMorph  imaging  software  (Molecular  Devices,  Toronto, Canada).  Invadopodia  were  analyzed  by  seeding  cells  on  a  thin  layer  of  FITC‐labeled gelatin  (VWR,  West  Chester,  PA)  as  previously  described  (56).  Cells  were  allowed  to invade for 20 hours, and the slides were then processed as described above, stained first for cortactin and then with Cy3‐anti‐mouse. Invadopodia were counted from 10 random fields in each sample (blinded) and averaged.  
 






2.3.1 Dasatinib inhibits proliferation and metabolism of MDA­MB­231 cells Building  on  the  observations  by  Finn  et  al  that  triple‐negative  and  basal‐type breast  cancer  cell  lines  were  more  sensitive  to  dasatinib  (133),  I  compared  three representative  breast  cancer  cell  lines.  MDA‐MB‐231  is  a  well‐characterized,  triple‐negative,  basal‐subtype  breast  cancer  cell  line.  MCF‐7  and  T47D  are  luminal‐subtype breast cancer cell lines that are positive for ER and PR. To determine the IC50 for the anti‐proliferative effects of dasatinib, a dose‐response curve was created for each cell  line by treating cells with dasatinib for 48 hours and quantifying metabolic activity using an MTT assay (Figure 12a). MDA‐MB‐231 cells were the most responsive (IC50 = 0.16 µM), while T47D demonstrated moderate growth inhibition (IC50 = 0.45 µM) and MCF7 showed very little response (IC50 = 12.3 µM). To confirm these results, cells were grown in dasatinib for 72 hours and counted at 24, 48 and 72 hours (Figure 12b). Again, MDA‐MB‐231 were the most sensitive; a dose‐dependent increase in doubling‐time was significant (p<0.01) after 72 hours for all three doses (0.05 µM, 0.1 µM, and 1.0 µM), where as only the highest dose for MCF7 was significant at 72 hours. Using cell‐counting data, the calculated IC50 values for MDA‐MB‐231 and MCF7 cells were 0.33 mM and 0.99 mM, respectively, a  three‐fold difference in sensitivity. Again, T47D were moderately sensitive. 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Figure 12: Dasatinib  inhibits  cell  proliferation  in  sensitive  cells. A) MTT assay of 





Because  the  calculated  IC50  values  were  higher  when  based  on  cell  counting,  I examined  the  viability  using  trypan‐blue  exclusion  and  replication  rates  using  BrdU uptake. Replicating MDA‐MB‐231 cells were significantly reduced from 35% to 12% with 100 nM dasatinib (Table 2), whereas the BrdU uptake rates were not significantly altered in MCF7 or T47D cells. Interestingly, there was no significant decrease in viability of the MDA‐MB‐231 cells upon dasatinib treatment. This lack of cell death was confirmed using flow cytometric quantification of annexin‐V and PI staining (data not shown). This is also demonstrated  by  western  blotting  for  PARP  cleavage  products  in  whole  cell  lysates  of MDA‐MB‐231 cells (Figure 17b).   
 
 







 The activation of Src is dependent upon the balance of two phosphorylation sites, the  activating  Tyr416  residue,  as  well  as  Tyr527,  which  maintains  Src  in  it’s  inactive, closed conformation. I examined the phosphorylation status of this inhibitory tyrosine, in response to dasatinib and found it to also be comparably inhibited across the three lines (Figure 13b). While  this could affect  the overall  inhibition of Src, dephosphorylation of Src‐Y527 was  only  significant  at  the  doses  10‐fold  higher  than  that  needed  for  Tyr416 inhibition.    At  this  level  of  dasatinib  dosing,  off‐target  effects  may  be  present  like inhibition of Csk (C‐terminal Src kinase) (139, 140).  





Clinical  applications  of  dasatinib  will  benefit  from  reliable  predictors  of  response.  To determine  whether  basal  Src  activity  might  predict  response  to  dasatinib,  I  compared starting levels of phospho‐Src (Y416) in a panel of breast cancer cells including MDA‐MB‐231, MCF7, and T47D (Figure 14a). Again, there were no dramatically different levels of Src phosphorylation  that  correlated with dasatinib‐response. One  cell  line  tested, MDA‐MB‐468,  demonstrated  high  levels  of  phospho‐Src  (Y416),  prompting  me  to  check  the dasatinib‐responsiveness  of  this  line.    As  with  the  initial  three  cell  lines,  phospho‐Src (Y416) was completely inhibited by 100 nM dasatinib (Figure 14b), suggesting that the high  level  of  basal  Src  activity did not  confer  resistance  to dasatinib. However,  the  IC50 based on metabolic inhibition (MTT assay) was greater that 10 µM (Figure 14c), similar to  the MCF7  line,  classifying  it  as  a  dasatinib‐resistant  cell  line.  Together,  these  results 
Figure 14:   Basal Src activity does not correlate with sensitivity. A) Western blot for phospho‐Src 
(Y416) and c‐kit  in untreated cell  lines. B) Dephosphorylation of Src  in dasatinib‐treated MDA‐MB‐
468 cells. C) MTT assay shows dasatinib‐response of MDA‐MB‐468 cells. 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demonstrate  that  basal  phospho‐Src  levels  and  dasatinib‐dependent  dephosphorylation are not reliable markers of dasatinib sensitivity in breast cancer cell lines.  Because dasatinib has also been reported to inhibit c‐kit, PDGFR, and EphA2 (130, 141‐143), it is possible that the effects of dasatinib are dependent on their inhibition. To this end, also screened the cell line panel for expression of these alternative targets. The most‐sensitive cell line, MDA‐MB‐231, did not express c‐kit or PDGFR (Figure 14a) (144, 145),  excluding  them  as  potential  targets.  Again,  only  the MDA‐MB‐468  line  expressed high levels of c‐kit, also indicating that is not an appropriate predictive marker. The MDA‐MB‐231  cells  did  express  high  levels  of  the  Ephrin  receptor,  however,  but  dasatinib treatment  did  not  affect  its  phosphorylation  status  (data  not  shown)  (146).  Based  on these  results,  these  alternative  targets  of  dasatinib  were  also  unreliable  predictors  of response. However, it remains possible that other, unknown targets of dasatinib are being inhibited and could prove to be effective predictors or markers or response. 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Figure  15: Dasatinib  induces  cell  cycle  arrest  in  sensitive  cells.  A)  Cell  cycle  distribution 
after dasatinib treatment. Cells were treated with indicated doses of dasatinib for 48 hours, 
stained for DNA content, and analyzed by flow cytometry. Graphs illustrate the percentage 
of  the  population  in  each  phase  of  the  cell  cycle.  **  represents  p  <  0.01  by  t‐test.  B) 
Inhibition of pCdk2 and accumulation of p27 after dasatinib  treatment.   Accumulation of 
Src‐targeted  p27  and  resulting  inhibition  of  Cdk2  correlate  with  G1  arrest  in  dasatinib‐
sensitive  MDA‐MB‐231  cells.  C)  Inhibition  of  Akt  after  dasatinib  treatment. 










2.3.3 Dasatinib treatment induces G1 arrest in MDA­MB­231 cells Because  dasatinib  impaired  proliferation  but  did  not  result  in  cell  death,  I  examined whether  dasatinib  could  block  cell  cycle  progression,  which  has  not  been  previously demonstrated in solid tumors. Therefore,  I employed flow‐cytometry to create cell cycle distribution profiles for each cell line after 48 hours of treatment with dasatinib (Figure 










2.3.4  Combination  treatment  of  dasatinib  and  doxorubicin  synergistically  inhibits 
metabolism  Small  molecule  inhibitors  are most  likely  to  be  used  in  combination  with  other chemotherapeutics  to  maximize  their  efficacy.  Therefore,  we  tested  the  effects  of dasatinib  in  combination  with  a  doxorubicin,  a  commonly  used  chemotherapeutic  in breast  cancer  to  determine  whether  the  two  drugs  might  synergize.  Doxorubicin (Adriamycin  ®)  is  an  anthracycline  antibiotic  that  intercalates  into  DNA,  inhibiting 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(dasatinib)  and  150  nM  (doxorubicin)  to  just  7.6  nM  of  each  drug.  In  T47D  cells,  this combination  lowered  the  individual  doses  from  453  nM  and  293  nM  for  dasatinib  and doxorubicin,  respectively,  to  6.6  nM  for  each  drug  when  combined.  These  results represent  a  95%  decrease  in  the  dose  of  doxorubicin  required  for  50%  metabolic inhibition of MCF7 cells and a 98% decrease in T47D cells. Given the toxic side effects of doxorubicin,  this synergy could have a profound effect on  the clinical use of a currently used chemotherapeutic.  To determine whether  the synergistic effects between dasatinib and doxorubicin could  also  been  seen  in  the  viability  or  replication  rates,  I  again  counted  cells  using trypan‐blue  exclusion  and  flow‐cytometric  quantification  of BrdU uptake  (Figure 16b). Combination treatment in MDA‐MB‐231 cells did not increase the percentage of dead cells over  the  rate  seen  with  doxorubicin  alone.  The  combination  treatment  did,  however, further  reduce  the  rate  of  BrdU  uptake  from  5.8%  (doxorubicin  alone)  to  3.9%.  In contrast,  MCF7  cells  demonstrated  no  significant  reduction  in  BrdU  uptake  with combination  treatment,  but  did  exhibit  a  decrease  in  viability  from  52%  (doxorubicin alone)  to  36.4%.  Although  there  was  obviously  a  dramatic  effect  on  proliferation, combination treatment did not result in any increased effect on the dephosphorylation of Src (Figure 16c). Whereas I demonstrated that dasatinib treatment of breast cancer cells results in a G1‐phase arrest, doxorubicin has previously been shown to cause G2/M arrest in actively growing cells  (147). To determine whether  the  cycle‐arresting effects of one drug  were  dominant,  I  again  used  flow‐based  cell‐cycle  analysis  of  cells  treated  with either 100 nM of each drug alone or in combination (Figure 17a).  In all three cell lines, the  G2/M  arrest  characteristic  of  doxorubicin  treatment  was  the  prevalent  effect  after combination  treatments.   After 48 hours of  combination  treatment, 82.6% of  live MDA‐MB‐231 cells were arrested  in G2/M phase, but  this was not  significantly different  than the  arrest  seen with  doxorubicin  alone  (82.1%  in G2/M).    Consistent with G2/M  arrest, accumulation of the CDK inhibitor p21WAF1 was evident after doxorubicin or combination treatment  in all  three cell  lines  (Figure 17b). Only minimal PARP cleavage was evident after  doxorubicin  treatment  and  no  increase  was  seen  after  combination  treatment (Figure  17b),  further  confirming  my  previous  results  that  any  cell‐death  is  occurring through a non‐apoptotic mechanism. 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treatment  was  sufficient  to  disrupt  their  morphology,  resulting  in  a  cell  that  was  still attached,  but  severely  rounded  and  contracted  (Figure  18a),  as  demonstrated  by immunofluorescence microscopy of cells probed for tubulin and actin. The morphology of MCF7 and T47D cells, which are of  the  luminal subtype and maintain a more epithelial‐like  shape  in  culture,  was  not  affected  by  dasatinib  treatment  (Figure  18b).  This  is consistent with the relatively resistant nature of these cells to dasatinib treatment. 
In an effort to differentiate the molecular pathways involved in the variable response to dasatinib,  I  probed  the  cell  line  panel  for  the  active  forms  of  Src  substrates  commonly implicated  in  cytoskeletal  rearrangement.  The  adaptor  protein  p130CAS,  which  is phosphorylated by Src downstream of integrin activation, was comparably inhibited in all three  cell  lines  (Figure  19a).    Similarly,  phosphorylation  of  FAK  at  the  Src‐targeted activating site, Tyr576, was comparably  inhibited  in all  three  lines. Consistent with  this 






was  the  observation  that  N‐WASp,  a  target  of  both  FAK  and  Src  that  mediates  Cdc42‐dependent Arp2/3 activation and actin nucleation, was inhibited in all three lines (Figure 
19b). It should be noted, however, that MCF7 cells exhibited lower basal phosphorylation of  p130CAS  and  FAK  (Y576)  than  either  the  MDA‐MB‐231  or  T47D  cells.  The  residual phosphorylation  after  100  nM  of  dasatinib  treatment,  however,  was  equal  despite  the starting levels. Of the proteins tested here, only inhibition of CrkL, the Cas‐related kinase, was variable across the cell lines. Dephosphorylation of CrkL at Tyr207 was strongest in the MDA‐MB‐231 cells and weakest in the MCF7 cells, a pattern similar to that seen with the  anti‐proliferative  effects  of  dasatinib.  Thus,  further  investigation  of  CrkL  (Tyr207) phosphorylation may be warranted as a potential marker for dasatinib response in breast cancer cells.  As  opposed  to  the  integrin‐mediated  signaling  of  Src  through  FAK,  Src  can  also target  the  Akt  survival  pathway  through  regulation  of  PI‐3K.  Therefore,  I  probed dasatinib‐treated cells for phospho‐Akt to determine whether this might contribute to the effects of dasatinib (Figure 15c). Indeed, MDA‐MB‐231 cells were the only line in which dasatinib  induced  the  dephosphorylation  of  Akt  at  Ser473.  As  is  common  in mesenchymal‐type  cells,  the  MDA‐MB‐231  cells  exhibit  heightened  levels  of  basal phospho‐Akt.  This  suggests  that  aberrant  activation  of  Akt  in  basal‐subtype  cells  may predispose  the cells  to  the anti‐proliferative effects of dasatinib.  It  should be noted  that while Akt can be directly  inhibited by dasatinib at high concentrations, the dose used in this  experiment  (100  nM)  is  well  below  the  published  IC50  for  Akt  (>50  μM).  Thus, dephosphorylation of Akt may serve as an effective biomarker for the response of breast cancer cells to dasatinib. 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2.3.6 Migration and invasion are inhibited by dasatinib treatment Given  the  highly  dynamic  morphology  of  MDA‐MB‐231  cells  and  the  dasatinib‐induced inhibition of cytoskeletal proteins (Figure 19), I investigated whether dasatinib could inhibit cellular migration and invasion of MDA‐MB‐231 cells. To accomplish this,  I quantified  wound‐healing  (scratch)  assays  to  compare  the  2D  migration  of  cells  after pretreatment with  dasatinib  (Figure  20a). Whereas  control‐treated  (DMSO)  cells were able  to  repopulate  the  denuded  area  within  16  hours,  this  migration  was  significantly inhibited with both doses (10 nM or 100 nM) of dasatinib (p<0.05). As a measure of 3D invasion and the ability of cells to degrade and penetrate a Matrigel layer, I used a Boyden chamber assay (Figure 20b). Treatment with dasatinib greatly reduced (88% reduction at 50 nM) the number of cells that had successfully invaded to lower chamber (p<0.01). Because MCF7  and T47D  cells  are  resistant  to migration  at  a wound  and  are unable  to invade Matrigel, they were not tested in these assays. It should also be noted that, because of  the  relatively  short  time‐point  at which  these assays were  completed,  the effects  are not the result of impaired proliferation.  Previous  studies  have  demonstrated  the  contribution  of  specialized  cytoskeletal structures known as invadopodia to the penetration of cells through extracellular matrix (54, 58, 76). These finger‐like projections are bundles of actin, which efficiently degrade the  extracellular matrix  via  secreted  and  transmembrane  proteinases.  In  cultured  cells, invadopodia can be visualized grown over a thin layer of FITC‐labeled gelatin. Using this method,  I counted the number of  invadopodia  formed per cell after dasatinib  treatment (Figure 21a) and found a dramatic decrease (more than 10‐fold) from an average of 5.4 (DMSO‐treated) to 0.4 invadopodia per cell (p<0.05 by t‐test).   Because  of  the  strong  anti‐proliferative  synergy  between  dasatinib  and doxorubicin,  I  also  tested  the  effects  of  combination  treatment  on  the  migration  and invasion of MDA‐MB‐231 cells (Figure 21b). Using the same methods as with individual treatment,  I  observed  a  small  decrease  in  migration  (approximately  20%)  with doxorubicin.  However,  this  was  significantly  improved  with  combination‐treated  cells (p<0.05).  Although the results were not statistically significant, this may even represent a small  improvement  on  the  inhibition  seen with  dasatinib  alone.  In  the Matrigel‐coated 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Figure  21:    Invadopodia  and  invasion  impaired  with  dasatinib,  doxorubicin 
combination.  A)  MDA‐MB‐231  cells  grown  over  FITC‐gelatin.  Active  invadopodia 
within  each  cell  degrade  the  gelatin  (arrows)  after  overnight  incubation.  B) Wound 
healing‐assay  after  pretreatment  with  dasatinib,  doxorubicin,  or  combination.  C) 






invasion assay, doxorubicin treatment alone resulted in impaired invasion comparable to dasatinib  alone  (approximately  90%  inhibition).  Combination  treatment,  however, significantly reduced the number of invading cells to approximately 5% of the untreated controls (Figure 21c, p<0.05). These data further support the investigation of dasatinib‐doxorubicin combination treatments to impair the proliferation, migration, and invasion of breast cancer cells. 
 
2.4 DISCUSSION 
  c‐Src  is  commonly  overexpressed  or  hyperactive  in  human  cancers,  including breast  cancer.  Because  of  its  role  at  the  crossroads  of  many  pathways  leading  to proliferation, survival, and migration, downregulation of Src  is an attractive  therapeutic target in the treatment of cancer. New small molecule inhibitors like dasatinib (Sprycel®) target both Src and Abl and are significant because of their relatively high selectivity and high affinity, making low clinical doses possible. Although dasatinib targets primarily Src and Abl  at  low,  nanomolar  concentrations,  it  can directly  target  other  tyrosine  kinases, such  as  Akt,  PDGFR,  c‐kit,  and  Ephrin  receptor,  at  higher  concentrations.  At  the concentrations  of  dasatinib  used  in  this  study,  however,  it  is  unlikely  that  dasatinib  is directly affecting the activity of other tyrosine kinases. Furthermore, I demonstrated that, in  the breast cancer cell  lines within  this work,  there are negligible  levels of expression and/or activation of other potential targets of dasatinib, including c‐kit, EphA2, and Abl.  In  these  experiments,  I  investigated  the  effects  of  dasatinib  on  a  small  panel  of breast cancer cell lines in an attempt to determine the molecular pathways underlying the variable  responsiveness  of  basal  versus  luminal  subtype  cells  to  dasatinib  that  had previously  been  described  (133).  Three  breast  cancer  cell  lines  were  tested  for  their response to dasatinib in proliferation, inhibition of Src signaling, migration, and invasion. Furthermore, I investigated the effects of combining dasatinib treatment with doxorubicin (Adriamycin), a common chemotherapeutic used in breast cancer. 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Initially,  I  found  that  the MDA‐MB‐231  cell  line, which  is  triple‐negative  (lacking ER,  PR,  and  HER2)  and  basal  sub‐type,  was  significantly  more  sensitive  to  the  anti‐proliferative  effects  of  dasatinib  than  the  ER‐,  PR‐positive,  luminal  subtype  MCF7  and T47D cell lines. However, Src inhibition, as measured by dephosphorylation of the Tyr416 activation site, was consistent in all three lines. This indicated that Src activation is not a reliable  marker  for  dasatinib  response,  despite  previous  reports  in  other  cell  systems (136,  137).  Although  some  loss  of  phosphorylation was  also  evident  at  the  inactivating site of Src (Tyr527),  this occurred at a much higher dose than that required  for Tyr416 dephosphorylation  and  also  did  not  correspond  with  anti‐proliferative  effects  of dasatinib. At high doses, dasatinib may also inhibit other tyrosine kinases like PDGFR and c‐kit,  however  these  kinases  were  not  present  in  MDA‐MB‐231  cells.  Although  the activation of Abl in MDA‐MB‐231 cells has previously been reported (149), I was unable to detect any basal phosphorylation of Abl  in the breast cancer cell  lines tested in these experiments  (data  not  shown).  Interestingly,  Gonzalez  et  al  demonstrated  decreases  in proliferation of MCF‐7 cells employing dominant‐negative and siRNA‐mediated inhibition of Src that were not evident with dasatinib‐mediated Src  inhibition (40) suggesting that the  non‐pharmacological  methods  of  Src  inhibition  may  have  stronger  effects  than dasatinib.  Because there was no difference in the inhibition of Src to explain the differences in anti‐proliferative effects,  I screened other potential markers of response. Others have reported downregulated mRNA levels of caveolin and moesin after dasatinib treatment of sensitive cells (133, 150). After dasatinib treatment of MDA‐MB‐231 cells, however, I was unable  to detect  and  change  in  the protein  levels  of  caveolin or moesin,  indicating  that actual  protein  levels may  not  be  suitable markers  of  response  (data  not  shown).  I  did identify a Src substrate, CrkL,  for which dephosphorylation correlated with proliferative inhibition. CrkL is an adaptor protein that associates with p130CAS and is phosphorylated at Tyr207 by FAK‐Src complex. This leads to activation of Rac, WAVE/WASp, and Arp2/3 and ultimately actin remodeling.  In  the dasatinib‐sensitive MDA‐MB‐231 cells, phospho‐CrkL (Y207) was decreased by 76%, compared with decreases of only 17% and 34% in 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the MCF7 and T47D cells, respectively. This observation warrants further exploration of CrkL activity as a marker for dasatinib response in breast cancer cells.   Downstream  of  EGFR,  Src  activation  also  modulates  activation  of  the  PI‐3K signaling cascade, leading to activation of the Akt/IKK/NFκB survival pathway (151). The more  mesenchymal‐like  MDA‐MB‐231  cells  demonstrated  high  basal  levels  of  Akt phosphorylation  (S473),  which  was  strongly  inhibited  by  100  nM  dasatinib  treatment. Neither basal  activity or dasatinib‐dependent  inhibition were evident  in MCF7 or T47D cells, suggesting that the phosphorylation status of Akt could be a biomarker to predict or measure  response  to dasatinib  in breast  cancer  cells. Kinase  assays have demonstrated that dasatinib  is capable of directly  inhibiting Akt activity, however  the  IC50  reported  in kinase assays is much higher (> 50 µM) than the 100 nM doses used in these experiments. Because several experiments in this study did not indicate any increases in apoptosis, it is unlikely that dasatinib is affecting cell survival pathways. Rather, Akt‐mediated effects on the cell cycle regulators Cdk2 and p27Kip1, may explain these results (152‐154).  The  vast majority  of  breast  cancer  related  deaths  are  the  result  of metastasis,  a complex  process  that  requires  the  acquisition  a  migratory  and  invasive  phenotype  by otherwise  non‐motile  epithelial  cells.  Therefore,  it  is  important  that  therapeutics  be identified  that  effectively  inhibit  the migration  and  invasion  of  cancer  cells.  Several  Src substrates,  such  as  FAK,  CrkL,  and  N‐WASp,  are  intimately  involved  in  adhesion  and reorganization  of  the  cytoskeleton.    Consequently,  dasatinib  treatment  dramatically altered the morphology of the mesenchymal‐like MDA‐MB‐231 cells in culture. In assays measuring migration (wound‐healing) and invasion (Matrigel‐coated Boyden chambers), MDA‐MB‐231  cells  were  greatly  impaired  (>90%  inhibition)  by  nano‐molar  doses  of dasatinib.  The  formation  of  invadopodia,  protrusive  structures  specialized  in  matrix degradation, is a critical component of efficient cellular invasion (54, 58, 155). Dasatinib‐treatment  of  MDA‐MB‐231  cells  significantly  decreased  formation  of  invadopodia, explaining  the  loss  of  cellular  invasion.  However,  invasion  is  a  complex  process  and  it cannot  be  excluded  that  other  functions  that  contribute  to  invasion,  such  as  matrix metalloprotease activation and secretion, may also be inhibited after dasatinib treatment. The  loss  of  branched  actin  structures  in  dasatinib‐treated  cells  suggests  a  loss  in  actin 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3.1 INTRODUCTION   Metastatic  tumors  are  responsible  for  the  majority  of  all  breast  cancer  deaths. Therefore, considerable research is aimed at predicting and preventing invasive behavior in  cancer  cells.  Metastasis  is  a  complex,  multistep  process  in  which  cancer  cells  must break away from a larger tumor mass, invade the surrounding tissue, enter, survive, and exit the circulatory system (either lymphatic or blood), and finally survive and proliferate in a distant organ (157). The initial steps in this cascade require a transition to a motile, mesenchymal‐like  phenotype.  Many  proteins  involved  in  cell  proliferation, apoptosis/survival, and motility have been identified with this “invasive signature” (158). EGFR  and  several  downstream  proteins  which  lead  to  actin  polymerization,  including Cdc42,  subunits  of  the  Arp2/3  complex,  and  cofilin  are  upregulated  in  rat  models  of mammary carcinoma (158). EGFR  activation  directs  actin  polymerization,  targeting  the  cell  towards  higher concentrations  of  EGF.  EGFR  signaling,  which  is  potentiated  by  Src  activity,  induces Arp2/3‐dependent  dendritic  nucleation  through  a  cascade  of  G‐proteins  and WASP/WAVE  family  members  (33,  158).    In  the  case  of  lamellipodia,  branched  actin networks are nucleated in response activation of Rac and WAVE. Bundled‐actin structures such as  filopodia and  invadopodia are dependent on Cdc42 and N‐WASp activation (42, 86, 88). N‐WASp activation is regulated through auto‐inhibitory folding that is relieved by its interaction with active Cdc42 and PI(4,5)P2 (159).   Phosphorylation of Tyr256 by Src family  kinases, which  occurs  only  in  the  open  conformation,  increases N‐WASp  activity (97,  160‐162).  A  central  proline‐rich  region  adjacent  to  the  Src  phosphorylation  site interacts  with  the  SH3  domain  of  CIP4  (101,  102).  CIP4  was  originally  identified  as  a binding partner of both GTP‐Cdc42 and Src family kinases (101, 102).  CIP4  is  a member  of  the  F‐BAR  family  of  proteins, with  FBP17  and  Toca‐1,  that dimerize via alpha‐helical BAR domains into amphipathic, crescent‐shaped structure that 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3.2.2 siRNA­mediated knockdown of CIP4 and N­WASp expression MDA‐MB‐231  cells were  transiently  transfected with 10 nM of CIP4 or N‐WASp‐directed  or  non‐targeting  siRNA  (Qiagen)  using  the  HiPerFect  transfection  reagent (Qiagen).  Decreases in protein expression were verified by western blotting of whole cell 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lysates,  as  described  in  Section  2.2.4.  After  72  hours,  cells  were  replated  for  the appropriate functional assay. 
 
3.2.2 Immunofluorescence and Invadopodia imaging Cells were  grown  on  glass  coverslips,  fixed  in  3.7%  formaldehyde  (30 minutes), permeabilized with 0.1% TritonX‐100 (5 minutes), and blocked in 1% BSA (30 minutes), each  at  room  temperature.    Samples  were  incubated  with  mouse  α‐CIP4  antibody overnight at 4o C,  followed by Cy3‐ or Cy5‐conjugated anti‐mouse and TRITC‐phalloidin for 1 hour at  room  temperature. Cells were  re‐fixed  in 3.7%  formaldehyde. Slides were prepared  using  ProLong  Antifade  with  DAPI  mounting  media  (Molecular  Probes),  and imaged  with  either  a  Nikon  Eclipse  TE2000U  microscope  with  MetaMorph  imaging software (Molecular Devices, Sunnyvale, CA) or Nikon A1 Confocal Microscope with Nikon NIS‐Elements software (Melville, NY). Gelatin  was  labeled  with  FITC  (Sigma)  in  0.1  M  bicarbonate  buffer  (pH  9.0), dialyzed extensively against PBS, and stored at 4o C.   FITC‐gelatin was crosslinked with 0.5%  glutaraldehyde  (10  minutes  on  ice  and  30  minutes  at  room  temperature)  and reduced with 1 mg/mL sodium borohydride (5 minutes at room temperature). Cells were plated on FITC‐gelatin‐coated dishes in complete media and allowed to invade for 16‐20 hours,  then processed as described above. Samples were stained with TRITC‐phalloidin. Invadopodia were counted from 6 to 10 random fields in each sample and averaged over multiple  experiments.  Gelatin  degradation  was  quantified  using  the  Macnification software (Orbicule BVBA, Heverlee, Belgium). 
 
3.2.3 Migration and Invasion Assays Migration was measured  by wound  healing  assay,  in which  cells were  grown  to 80% confluence in 6‐well plates and streaked with a sterile pipet tip to create a wound.  The wound width was measured  at marked  locations  immediately  after wounding  and again after 24 hours of recovery time. Measurements were taken at mutiple points along the  length  of  the wound  to  create  an  average  for  each  individual  wound,  and  samples were  tested  in  triplicate.  Invasion  assays  were  performed  using  Matrigel  invasion chambers (BD Biosciences, Bedford, MA) seeded with 2.5 x 104 cells per well. Complete 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media was used in both the upper and lower chambers, with or without 100 ng/mL EGF added only to the lower chamber. Cells were allowed to invade for 24 hours through the Matrigel and 8 mm‐pore membrane, at which point the inserts were removed, the upper side of  the membranes were scrubbed. The cells were  then  fixed  in methanol,  rinsed  in distilled water (1 minute each), air‐dried, and mounted on slides with ProLong Antifade with  DAPI  (Molecular  Probes).  Membranes  were  visualized  with  Zeiss  epifluorescence microscope to count the number of invading cells in 9 random fields per sample. Samples from multiple experiment were averaged.  
 
3.2.4 Acceptor­photobleaching FRET Acceptor photobleaching FRET (apFRET) was used to quantify the EGF‐dependent interactions  between  CIP4/N‐WASp.    All  images were  recorded  using  a  Zeiss  LSM  510 confocal  microscope  using  a  63X,  1.3  NA  objective.    apFRET  was  applied  largely  as described previously where bleach settings are defined empirically (164, 165). Briefly, a cell expressing YFP‐CIP4 and CFP‐N‐WASp was selected and 3 regions of interest (ROIs) were drawn for YFP bleaching and controls.  The large ROI (ROI 3) was scanned 10 times using  routine  scanning  settings.    The  bleach  ROIs  (ROI1)  region  was  then  bleached  at 100% intensity for 1000 iterations or approximately 3 min.  One ROI (ROI 2) was drawn to measure  any  potential  for  off‐target  bleaching, which  accounted  for  less  than  1%  of changes  in  YFP  and  CFP.    Following  the  bleach,  10  more  scans  were  taken  using  the prebleach  settings.    The  FRET  efficiency  (increase  in  CFP  upon  YFP  bleaching)  was calculated using the following equation:    Furthermore,  the  distance  between  fluorophores  was  calculated  by  solving  the equation for r: 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3.3.1 Invasive breast cancer cell lines express high levels of CIP4 To  determine  whether  CIP4  expression  levels  correlated  with  invasiveness,  I compiled  a  panel  of  breast  cancer  cell  lines  of  varying  invasiveness.  Based  on previous studies, MDA‐MB‐231 and Hs578T  cells  are highly  invasive  in  in  vitro  Boyden  chamber assays  (1)  and  also  invade  and  metastasize  in  nude  mice  (Table  4)  (66).  In  contrast, MCF7, T47D, and SKBR3 cells are weakly or non‐invasive in vitro (1).  These two groups correspond  with  basal  (MDA‐MB‐231  and  Hs578T)  and  luminal  (MCF7,  T47D,  and SKBR3) subtypes (1). Through immunoblotting, I found that CIP4 protein expression was elevated in the invasive lines as compared with the weakly‐ or non‐invasive lines (Figure 
23a). This  trend was not seen with FBP17 or Toca‐1  (Figure 22a). This difference was statistically  significant  (p<0.05)  based  on  densitometric  quantification  (Figure  22b). 
Table 4: Comparison of invasive behaviors in breast cancer cell lines 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Expression  of  CIP4  was  also  upregulated  at  the  mRNA  level  in  the  MDA‐MB‐231  cells (Figure 22c), whereas  this pattern was not evident with FBP17 or Toca‐1. The average 
Figure 22: Overexpression of CIP4  in  invasive breast  cancer  cell  lines. A) Western blot of 
CIP4,  FBP17,  and  Toca‐1  in  breast  cancer  cell  line  panel.  B)  Quantification  based  on 





CIP4  mRNA  level  was  6.3‐fold  higher  in  MDA‐MB‐231  cells  compared  with  MCF‐7  (p=0.009) and 2.8‐fold higher versus T47D (p=0.026). 
Our work in the Corey lab and others have identified multiple isoforms of CIP4 that 
lack functional SH3 domains due to retained intronic sequences (102, 109). Because this 
structure could have a profound impact on the function of CIP4, I used PCR amplification and 
digestion to determine whether any of these alternative isoforms were present in the breast 
cancer cell lines. I screened MDA-MB-231, MCF7, and T47D cell lines for the five CIP4 
isoforms (Figure 8b), and found that only CIP4a, the ubiquitously expressed, full-length 
protein, was expressed (data not shown). Therefore, all discussion of CIP4 here refers to the 
CIP4a isoform. 
 





other biomarker status (p=1.03x10‐7,  t‐test). Again, no significant difference was seen in the expression of FBP17 or Toca‐1 (Figure 23).  Because of the membrane‐binding properties conferred by the F‐BAR domain, subcellular localization may  affect  its  function.  I  compared  the  localization  of  endogenous  CIP4  in MDA‐MB‐231 cells with MCF7 and MCF10a (non‐cancerous mammary cell line) and found that CIP4 was enriched at  the plasma membrane  in only  the  invasive MDA‐MB‐231 cell line (Figure 24, arrows). MCF7 and MCF10a had little CIP4 at the plasma membrane.  
 








C)  Wound‐healing  assay  at  0  and  24  hour  after  wound  in  CIP4‐depleted  cells. 








3.3.3 CIP4 controls N­WASp activation in response to EGF EGF stimulation activates N‐WASp via Cdc42 (91, 167).   Given that CIP4 interacts with  Cdc42  (101)  and  localizes  with  EGFR‐containing  vesicles  (168),  I  speculated  that CIP4  might  interact  with  N‐WASp  in  an  EGF‐dependent  manner.  Initially,  co‐immunoprecipitation experiments indicated that EGF transiently increased CIP4‐N‐WASp interaction at around 1 minute after  treatment  (data not shown). To confirm this effect and  investigate  the  kinetics  more  precisely,  we  used  acceptor  photobleaching  FRET microscopy to quantify the energy transfer between YFP‐CIP4 and CFP‐N‐WASp in MDA‐MB‐231  cells.  Indeed,  EGF  treatment  produced  a  spike  in  interaction  at  around  10 seconds (Figure 26a). 
D 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Figure 26:   CIP4  interacts  and  increases activation of N‐WASp downstream of  EGFR.  A) 
Quantification of apFRET experiments demonstrating increase in interaction between YFP‐














The  Src‐targeted Tyr256 of N‐WASp  is  only  accessible  in  the open  conformation and  is  associated  with  increased  activity  (97,  160‐162).  Therefore,  I  used  the phosphorylation status of Tyr256 as a surrogate marker for N‐WASp activity downstream of  EGFR  activation.  In  control  cells,  stimulation  of  EGFR  increased  N‐WASp phosphorylation  (Figure  26b).  To  determine  whether  the  expression  level  of  CIP4 affected N‐WASp activation,  I  immunoblotted  for phospho‐N‐WASp  in control and CIP4‐depleted  cells  treated  with  EGF.  This  demonstrated  that  CIP4  is  required  N‐WASp phosphorylation  in  resting and EGF‐stimulated cells,  suggesting  that CIP4 promotes  the activation of N‐WASp.   













3.3.5 CIP4 promotes invasion of MDA­MB­231 cells in vitro Because  invadopodia  formation correlates with cellular  invasion,  I  continued  the study of CIP4 knockdown in MDA‐MB‐231 cells to Boyden chamber assays. After 72 hours of CIP4‐siRNA treatment, cells were transferred to Matrigel‐coated chambers and allowed to  invade  for  an  additional  24  hours.  CIP4‐depletion  by  two‐independent  siRNA sequences  demonstrated  that  CIP4  loss  significantly  inhibited  invasion  (Figure  30a, p<0.01)  as  compared  with  control  cells.  This  represents  a  decrease  in  invasion  of approximately 76%, which  is  similar  to  the degree of  inhibition with N‐WASp‐siRNA or Src‐inhibition (Figure 20b).  Although MDA‐MB‐231 cells invade through Matrigel spontaneously, the presence of  EGF  in  the  lower  chamber  can  increase  their  rate  of  invasion  (Figure  30b).  This responsiveness  to  EGF  was  completely  abrogated  by  CIP4‐depletion. 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Figure 29:  CIP4 required for basal and EGF‐dependent invasion. A)  Matrigel‐coated Boyden 











triple‐negative  breast  cancer  cell  line  MDA‐MB‐231  as  a  model,  I  found  that  siRNA‐mediated depletion of CIP4  impaired the 2D migration of cells  in wound‐healing assays. This reinforces the notion that CIP4 regulates the actin cytoskeleton. While Cdc42 and N‐WASp are not  typically  implicated  in  lamellipodia  formation,  they are both required  for the  formation  of  the  direction‐sensing  filopodia  at  the  leading  edge  of  the  cell.  Loss  of CIP4 may impair mechanisms of filopodia formation, therefore disrupting directional cell migration.  N‐WASp serves as  a major  effector  for  the Rho GTPase Cdc42, mediating Cdc42‐dependent Arp2/3 activation and actin polymerization (47, 94, 98, 159, 169). Previously, Ho  et  al  demonstrated  that  TOCA‐1,  a  related  F‐BAR  protein,  strengthens  the  Cdc42‐mediated  activation  of  N‐WASp,  resulting  in  increased  actin  polymerization  in fluorescence‐based,  cell‐free  assays  (105).  Using  liposomes,  Takano  et  al  demonstrated that  FBP17  and  Toca‐1  increased  N‐WASp‐mediated  actin  polymerization  through  a membrane‐curvature  dependent  mechanism.  I  hypothesized  that  CIP4  may  function through  a  similar  mechanism,  stabilizing  the  activation  of  N‐WASp.  Because  N‐WASp activation at  the plasma membrane is  increased downstream of EGF (71),  I  investigated whether  the  interaction  between  CIP4  and  N‐WASp  might  also  be  responsive  to  EGF stimulation.   Through  co‐immunoprecipitation  and  apFRET  microscopy,  I  demonstrated  that the interaction between CIP4 and N‐WASp is rapidly and transiently increased after EGFR activation.  The  peak  in  interaction  was  seen  at  approximately  10  seconds  after stimulation and lingers for approximately one minute. This time‐frame corresponds with the activation of a FRET‐based N‐WASp biosensor, as demonstrated by Lorenz et al (71).  Activation  of  N‐WASp  is  regulated  through  auto‐inhibitory  folding,  which  precludes phosphorylation  of  Tyr256  by  Src/FAK  (97,  162,  170).  In  the  absence  of  CIP4,  basal phosphorylation  of  Tyr256  was  decreased  and  EGF‐induced  phosphorylation  was abrogated. While not a direct measure of N‐WASp activation, phospho‐Tyr256 has been correlated  with  activation  and  actin  polymerization  (97,  162,  170).  This  suggests  that CIP4 expression is required for N‐WASp activation. 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The EGFR‐Cdc42‐N‐WASp signaling pathway has been implicated in the formation of  invadopodia,  actin‐based  protrusions  that  are  specialized  in matrix  degradation  (68, 74, 91). Since CIP4 may participate in this cascade, I examined the invadopodia formed by MDA‐MB‐231 cells in culture through immunofluorescence microscopy. Along with actin, CIP4 was enriched at active  invadopodia. CIP4‐depletion decreased both  the number of invadopodia  formed and  the area of gelatin‐degradation per cell,  indicating  that CIP4  is critical  to  the  formation  and  function  of  invadopodia.  No  F‐BAR  family  members  have been previously associated with invadopodia of cancer cells. Through ELISA assays, I was able  to  detect  a  small  decrease  in  the  secretion  of  MMP‐9,  a  gelatin‐specific metalloprotease that is relevant in invadopodia. However, the 20% inhibition in MMP‐9 is unlikely  to  account  for  the  approximately 75% decrease  in  invadopodia  formation. The loss  of  invadopodia  and  gelatin  degradation  associated  with  CIP4  knockdown  was comparable to that seen with depletion of N‐WASp, which is well established as a critical component of invadopodia formation.  Invadopodia are important to cellular invasion, so I examined whether the loss of CIP4 would affect the invasiveness of MDA‐MB‐231 cells in vitro. I found that loss of CIP4 dramatically  inhibited  invasion  through  a  Matrigel  layer  and  abrogated  the chemoinvasive behavior  towards EGF. This supports  the hypothesis  that CIP4 promotes invasion through the Cdc42‐N‐WASp signaling pathways.   CIP4’s structure suggests that it functions as a scaffolding protein to promote actin polymerization at areas membrane curvature by  integrating N‐WASp regulation with F‐BAR  mediated  membrane  curvature.  Through  upregulation  of  this  mechanism,  CIP4 overexpression  may  contribute  to  the  invasive  phenotype  of  triple‐negative,  EGFR‐positive  breast  cancers.  These  results  support  the  further  investigation  of  CIP4  as  a potential biomarker for invasive breast cancers. 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CHAPTER 4:  GENERAL SUMMARY Invasion  is a phenotypic hallmark of  cancer  that can  lead  to metastasis, which  is associated with a poor prognosis (9, 157). Five‐year survival rates decrease sharply with diagnosis  of  advanced  breast  cancer  (23.3%)  compared with  localized  disease  (98.3%) (2). One subtype of breast cancer that is associated with aggressive disease and increased metastasis is the “triple‐negative” tumors, frequently of the basal subtype. These cancers are  refractory  to  current  anti‐HER2  targeted  therapy  (166,  171)  and  frequently overexpress the EGF receptor (EGFR), which also correlates with  invasiveness and poor prognosis (172). Therefore, anti‐invasion therapies could have a significant impact on the treatment  of  advanced  breast  cancers.  Several  proteins  have  been  associated  with  the invasive phenotype, many of which are  linked  to  the  cytoskeletal  system,  including Src, Cdc42, N‐WASp (31, 63, 173).  My experiments address the role of the tyrosine kinase Src and the F‐BAR protein CIP4  in  promoting  the migration  and  invasion  of  breast  cancer  cells  in  vitro.  Increased expression and activity of Src  is common in human breast cancers and  is  frequently co‐expressed with elevated EGFR. I demonstrated that inhibition of Src through dasatinib, a small molecule inhibitor of Src and Abl, impairs not only the proliferation of human breast cancer  cells,  but  also  their  migration  and  invasion  in  in  vitro  assays  (173).  Although dasatinib  has  been  approved  for  the  treatment  of  imatinib‐resistant  leukemias,  clinical testing  of  dasatinib  in  solid  tumors  is  still  ongoing.  Combination  therapies  that  include dasatinib  have  not  previously  been  studied  in  breast  cancer. My  data  presents  a  novel finding  that  dasatinib  and  the  anthracycline  doxorubicin  synergistically  inhibit  cell proliferation,  representing  a  significant  decrease  (greater  than  40‐fold)  in  the  dose  of doxorubicin required for 50% inhibition of cell proliferation. Because Src is involved in a wide variety of signaling pathways, the exact mechanism of this synergy is still unknown. In my research, I was unable to identify cooperative inhibition of any single pathway as a result  of  combination  treatments.  This  may  suggest  that  the  synergistic  inhibition  of proliferation  is  the  result  of  blockages  in  independent  pathways.  Src  inhibition  also significantly  impairs  cell  migration  and  invasion  of  the  clinically  significant  “triple‐negative” breast  cancer  cells, which are associated with a higher  rate of metastasis. My 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data  suggests  that  this  inhibition  occurs  through  downstream  inhibition  of  the cytoskeletal regulators N‐WASp and FAK.  Another  Src‐associated  protein  is  the  F‐BAR  protein  CIP4,  which  also  interacts with N‐WASp. My  preliminary work  demonstrated  that  CIP4  is  upregulated  in  invasive breast  cancer  cells,  leading  me  to  investigate  its  contribution  to  cytoskeletal reorganization. Analysis of CIP4 mRNA expression in a larger set breast cancer cell lines confirmed that CIP4 was elevated in “triple‐negative” cell lines, which are typically more invasive.  To correlate CIP4 expression with invasiveness in patient samples, I attempted to  stain  tissue  samples  with  anti‐CIP4  antibodies.  However,  immunohistochemical staining  for CIP4 (with multiple commercially available and homemade antibodies) was never  successful,  possibly  due  to  poor  retrieval  of  CIP4  antigen  or  degradation  of  CIP4 before the fixation process. Because of this lack of reliable IHC staining, the development of CIP4 as a biomarker of invasion is limited.  CIP4  is  considered  a  scaffolding  protein  that  recruits  N‐WASp  and  dynamin  to areas  of  membrane  curvature.  My  results  demonstrate  that  CIP4  also  regulates  the activation  of  N‐WASp  downstream  of  EGFR  activation.  I  have  also  shown  that  CIP4 depletion significantly  impairs the migration and invasion of breast cancer cells  in vitro. Takano et al described a model in which the static repulsion between acidic residues near the SH3 domain of FBP17/Toca‐1 and the hydrophobic plasma membrane forces the SH3 domain away from the membrane where it binds N‐WASp and stabilizes its binding to the membrane (127). Building on this model, I propose that a similar arrangement is present in  CIP4  dimers  bound  to  the  plasma  membrane.  As  static  repulsion  pushes  the  SH3 domain away  from the plasma membrane and  the hydrophobic outer  face of  the F‐BAR domains, CIP4 acts as a stabilizer for the open conformation of N‐WASp (Figure 10). N‐WASp binds the plasma membrane directly through its basic region, tethering one end of the  protein  to  PI(4,5)P2‐enriched  membranes.  The  interaction  with  CIP4  serves  two functions: Firstly, binding to CIP4 localizes N‐WASp to areas of membrane curvature such as budding vesicles or invadopodia. Secondly, the spring‐like action of CIP4 holds N‐WASp in an open conformation, potentiating its activation by increasing access to the Src/FAK‐
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targeted  phosphorylation  site  (Tyr256)  and  the  Cdc42  (GTPase)‐binding  domain.  GTP‐Cdc42 and Src phosphorylation are both associated with  increased actin polymerization via N‐WASp(96, 97, 159). Our  lab  initially  identified CIP4 as  a novel binding partner of SFKs  and  has  demonstrated  Src‐dependent  phosphorylation  (unpublished  results) adjacent  to  the  acidic  region  described  by  Takano  et  al.  Therefore,  I  propose  that phosphorylation  of  CIP4  by  Src  increases  the  hydrophobic  nature  of  this  region  and increases  the  electrostatic  repulsion  holding  CIP4’s  SH3  domain  away  from  the membrane. Essentially, this stiffens the spring action of CIP4 at the plasma membrane and further strengthens the stabilization of open N‐WASp.  F‐BAR  proteins  have  not  previously  been  identified  at  invadopodia.  My  data demonstrate the novel finding that CIP4 is localized to invadopodia of breast cancer cells 











CHAPTER 5:  FUTURE DIRECTIONS   My  experiments  with  dasatinib  inhibition  of  Src  demonstrated  a  high  degree  of synergy  with  doxorubicin  in  impairing  cell  proliferation.  However,  the  mechanism underlying this phenomenon is still unclear. Future research into combination therapies including  both  dasatinib  and  doxorubicin  should  focus  on  the molecular  pathways  that account for the Src‐dependent resistance to doxorubicin in breast cancer cells.   Although research in our lab identified a Src phosphorylation site within CIP4, the effects  of  this  modification  are  unknown.  I  have  postulated  that  this  phosphate  group increases  the  electrostatic  repulsion  that  forces  the  SH3 domain  away  from  the plasma membrane,  stiffening  the  spring‐like  mechanism  by  which  CIP4  stabilizes  the  open conformation of N‐WASp. A major drawback in the study of CIP4 is the current lack of any measure of CIP4  function. Similar  to  the FRET‐based studies described by Takano et al, the  structural  arrangement  of membrane‐bound  CIP4  and N‐WASp  could  be  studied  in response to Src phosphorylation and the availability of curved membranes.  Disruption of the phosphorylation by Src, which could be accomplished with dasatinib treatment, may weaken  the  spring‐action  of  CIP4  and  impair  its  ability  to  stabilize  the  open  N‐WASp conformation.  Cell‐free  actin  polymerization  assays may  provide  a  quantifiable method for measuring CIP4 function. Src inhibition through dasatinib could be used to study the effects on CIP4  through  these assays.   Furthermore,  the Src binding region of CIP4 may also allow it to act as a scaffold to directly promote N‐WASp phosphorylation by Src at the plasma  membrane.  The  establishment  of  CIP4  as  a  downstream  effector  of  Src  would represent a novel pathway in the Src‐signaling cascade. These experiments could initially be carried out using cell‐free,  liposome based assays but would be more relevant when performed  in  invadopodia  model  systems.  Because  F‐BAR  interaction  with  the  plasma membrane is curvature‐dependent, cells grown on standard culture surfaces may not be the  optimal  models.  Rather,  cells  grown  on  gelatin,  allowing  formation  of  invadopodia may  provide  more  sites  for  formation  of  these  complexes.  Furthermore,  efficient activation of  integrins by the presence of extracellular matrix may also encourage these complexes. 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Mutants of CIP4 that  lack functional binding sites for N‐WASp or Cdc42 or which carry point mutations in the Src‐phosphorylation site would be useful tools in elucidating which interactions are critical the function of CIP4.  Biochemical experiments are needed to determine whether CIP4 is required for N‐WASp interaction with Cdc42. Because CIP4 overexpression correlates with invasiveness, biochemical studies should be performed to determine the effects of saturating concentrations of CIP4 in comparison to N‐WASp and Cdc42. The SH3 domain of CIP4 also interacts with dynamin, an important component of vesicle  fission.  Dynamin  is  also  found  in  invadopodia,  although  its  function  there  is unknown.  More  research  is  needed  to  determine  whether  CIP4  is  required  for recruitment of dynamin to invadopodia or in some way contributes to its function.  My  results  clearly  demonstrated  increased  CIP4  expression,  at  the  mRNA  and protein  levels,  in  invasive  and  “triple‐negative”  breast  cancer  cell  lines.  However,  the regulation  of  CIP4  expression  has  not  previously  been  examined.  Because  “triple‐negative” cell lines frequently express high levels of EGFR, it is possible that transcription factors activated downstream of EGFR are responsible for CIP4 expression.  The time‐line of invadopodia formation is not well understood, therefore the stage at which CIP4 and N‐WASp are recruited to invadopodia is unknown. Live‐cell time‐lapse microscopy,  using  fluorescently  tagged  CIP4  and  N‐WASp would  demonstrate  whether CIP4  is  required  for  the  early  formation  of  invadopodia  or  the maintenance  of  a more stable  structure.  If  CIP4  is  required  for  laying  the  initial  base  of  branched  actin, invadopodia  formation  will  be  impaired  at  a  very  early  stage  of  development.  Breast cancer  cells  that  stably  express  fluorescently  labeled  actin  monomers  would  be  very useful for this assay.   I demonstrated that CIP4‐depletion severely impairs the cellular invasion of breast cancer cells  in vitro, however  this  should be  transferred  to animal models  to determine whether inhibition of CIP4 leads to an inhibition in metastasis. Because the experiments here  represent  localized  invasion,  the most  germane  experiments would  focus  on  local tissue  invasion  of  orthotopic  tumors  in  nude mice,  as  evaluated by  histological  studies. Our work  in  the Corey  lab has produced CIP4‐null  transgenic mice  (174), which have a minimal  phenotype  of  rapid  clearance  of  blood  glucose  resulting  from  delayed endocytosis  of  the  GLUT4  glucose  transporter.  Although  the  mice  do  not  suffer  any 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obvious defects  in normal cell migration  in development,  it  is possible  that  loss of CIP4 may  play  a  more  specific  role  in  the  invasive  process  of  transformed  epithelial  cells. Therefore, cross‐breeding of the CIP4‐null mice with mouse models of metastasis, such as the MMTV model, would be useful to determine the contribution of CIP4 to invasion and metastasis of spontaneously generated tumors in vivo. Such a system would also be useful in determining the importance of CIP4 in Src‐dependent pathways, using dasatinib as an anti‐metastatic  agent.  Because  of  the minimal  phenotype  of  the  CIP4‐null mice  and  the close  homology  of  CIP4  to  FBP17  and Toca‐1,  the  generation  of  triple‐knockout mouse could produce a stronger effect on development or other normal migratory processes. 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